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English Abstract 
Introduction: The development of intestinal failure is the consequence of diverse 
aetiologies and pathophysiological causes. Fistuloclysis is an effective means of 
nutritional support in selected intestinal failure patients. This study aimed to 
investigate the management of adult intestinal failure patients in hospitals in South 
Africa, determining how practical and acceptable fistuloclysis is. 
 
Methods: The study included three phases. Phase 1 consisted of a retrospective 
record review of adult patients admitted to Groote Schuur Hospital Intestinal Failure 
Unit between January 2009 and May 2014. Data collected included demographics, 
surgical interventions, gastrointestinal anatomy, nutritional management, 
biochemical markers and intake and output. Phase 2 consisted of a purposefully 
selected case study report published in a peer-reviewed journal. Phase 3 
investigated the current management of type 2 and type 3 intestinal failure patients 
in South African hospitals, evaluating perceptions and opinions among South African 
doctors, stoma therapists and dietitians by means of occupation-specific 
questionnaires.  
 
Results: Phase 1: Seventeen intestinal failure patients receiving fistuloclysis were 
included in the study. During the fistuloclysis period, the median daily output was 1 
478ml with a median of 71% of effluent received back via fistuloclysis. Four patients 
went home for a median period of 32,5 days on fistuloclysis. There was a statistically 
significant increase in the median albumin level between day 0 and day 28 of 
fistuloclysis, however body weight did not improve during this period. Postoperative 
complications occurred in only three patients. Patients were discharged after a 
median of 12 days post definitive surgery, with three complicating postoperatively 
and all patients regaining nutritional autonomy.  
 
Phase 3: Twenty-seven dietitians participated in the survey, the majority (67%) 
having been involved with patient management in this field for one – five years. All 
indicated high fistula outputs would be defined as intestinal failure. Only 47% gave 
the correct definition, with 28% currently utilising fistuloclysis. All respondents agreed 
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that unsuccessful implementation of fistuloclysis was due to training shortfalls and 
resistance from clinicians and nursing staff.  
 
Ten stoma therapists entered the survey but only two fitted the inclusion criteria. 
Both worked in the private sector,  with >10 years of experiece in the management of 
intestinal failure patients. Only one of the two proceeded with further questions. 
 
Four doctors managing intestinal failure responded. All respondents indicated high 
fistula outputs as associated with intestinal failure. The aetiology of intestinal failure 
indicated was postoperative complications by 75% of the respondents. The majority 
of respondents (75%) indicated that keeping patients nil by mouth was common 
practice, 50% of respondents indicated routine usage of pharmacological agents to 
decrease output or transit time. All respondents gave the correct explanation of 
fistuloclysis with 50% currently using fistuloclysis. 
 
Conclusion: Fistuloclysis is not superior, but equivalent to conventional methods of 
intestinal failure management. From this study and other available literature it is 
evident that fistuloclysis can replace PN support in selected patients. From the 
different occupation group surveys it is evident that there is a positive perception and 
awareness of fistuloclysis; however numerous stumbling blocks hamper the wider 
use of this novel treatment. 
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Afrikaanse Opsomming 
Inleiding: Die ontwikkeling van intestinale versaking is die gevolg van diverse 
etiologieë en patofisiologiese oorsake. Fistuloklisie is 'n doeltreffende manier van 
voedingsondersteuning vir geselekteerde pasiënte. Hierdie studie was daarop gemik 
om die behandeling van volwasse pasiënte met intestinale versaking in hospitale in 
Suid-Afrika te ondersoek en te bepaal hoe prakties en aanvaarbaar fistuloklisie is. 
 
Metodes: Die studie het bestaan uit drie fases. Fase 1 was 'n retrospektiewe 
rekordhersiening van volwasse pasiënte wat tussen Januarie 2009 en Mei 2014 in 
Groote Schuur Hospitaal se eenheid vir intestinale versaking opgeneem is. Data wat 
ingesamel is, sluit in demografiese gegewens, chirurgiese intervensies, gastro-
intestinale anatomie, voedingsbehandeling, biochemiese merkers en vloeistofbalans. 
Fase 2 was ‘n doelgerigte gevallestudie wat gepubliseer is in 'n vaktydskrif. Fase 3 
het gebruik gemaak van beroepspesifieke vraelyste om huidige behandeling van 
pasiënte met tipe 2 en 3 tipe intestinale versaking in Suid-Afrikaanse hospitale te 
ondersoek, sowel as persepsies en menings oor fistuloklisie onder Suid-Afrikaanse 
dokters, stomaterapeute en dieetkundiges te bepaal. 
 
Resultate: Fase 1: Sewentien pasiënte met intestinale versaking wat behandel is 
met fistuloklisie is ingesluit in die studie. Gedurende die fistuloklisietydperk was die 
mediaan uitskeiding 1 478ml per dag met 'n mediaan van 71% wat teruggeplaas is 
deur fistuloklisie. Vier pasiënte kon ontslaan word vir 'n mediaantydperk van 32,5 
dae op fistuloklisie. Daar was 'n statisties beduidende toename in die 
mediaanalbumien vlak tussen dag 0 en dag 28 van fistuloklisie, maar liggaamsgewig 
het nie verbeter nie. Chirurgiese komplikasies het by slegs drie pasiënte voorgekom. 
Pasiënte is ‘n mediaan van 12 dae na chirurgie ontslaan en alle pasiënte het 
voedingsoutonomie herwin. 
 
Fase 3: Sewe en twintig dieetkundiges het aan die opname deelgeneem. Die 
meerderheid (67%) het een tot vyf jaar ondervinding gehad in die behandeling van 
pasiënte. Almal het aangedui dat hoë fisteldreinering gedefinieer sou word as 
intestinale versaking. Slegs 47% het die korrekte definisie vir fistuloklisie gegee, 
terwyl 28% tans daarvan gebruik maak. Al die respondente het saamgestem dat 
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onsuksesvolle implementering van fistuloklisie te wyte is aan ‘n tekort aan opleiding 
en weerstand van dokters en verpleegpersoneel. 
 
Tien stomaterapeute het deelgeneem, maar slegs twee het voldoen aan die 
insluitingskriteria. Albei was werksaam in die privaatsektor, met >10jaar ondervinding 
in die behandeling van hierdie pasiënte. Slegs een het die vraelys verder voltooi. 
 
Vier dokters het die vraelys voltooi. Almal het hoë fisteldreinering geassosieer met 
intestinale versaking. Die etiologie van die intestinale versaking is aangedui as 
chirurgiese komplikasies deur 75% van respondente. Die meerderheid van 
respondente (75%) het aangedui dat dit algemene praktyk is om pasiënte nil per 
mond te hou, terwyl 50% roetineweg farmakologiese middels voorskryf om 
dreinering of deurgangstyd te verminder. Al die respondente het die korrekte 
definisie van die term gegee terwyl slegs 50% tans fistuloklisie gebruik. 
 
Gevolgtrekking: Fistuloklisie is gelykstaande aan konvensionele behandeling van 
intestinale versaking. Uit die resultate van hierdie studie en beskikbare literatuur is 
dit duidelik dat fistuloklisie parenterale voeding by gepaste pasiënte kan vervang. Uit 
beroepsopnames is daar 'n positiewe persepsie en bewustheid van fistuloklisie, 
maar ook talle struikelblokke wat die wyer gebruik belemmer. 
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Intestinal failure (IF) and the complications and cost associated with parenteral 
nutrition (PN) support in this patient population are a reality at Groote Schuur 
Hospital. Owing to the nature and complexity of IF it often requires long-term 
hospitalisation and PN support to improve or maintain nutritional status, allow for 
enough time between surgeries for peritoneal adhesions to resolve and time to treat 
current complications before a patient can be considered for definitive surgery.(1,2) 
Internationally, and at Groote Schuur Hospital, specialised units adhere to a waiting 
time before definitive surgery ranging between six weeks and six months.(1,2) In a 
recent cost analysis done by the National Department of Health, PN was found to be 
under the top 10 pharmacy expenditures, contributing major costs to patient 
treatment.(3) Groote Schuur Hospital started a unit specialising in managing IF 
patients in 2009 and currently has a six-bed cubicle within the colorectal surgery 
ward where these patients are managed. Fistuloclysis has been successfully 
implemented within this unit as a means of nutrition support and in doing so it has 
been possible to wean patients off PN support and eliminate the cost and negative 
side effects associated with it. Doctors, nursing staff, stoma therapists and dietitians 
involved in this unit are familiar with, and experienced in, the field of IF and 
fistuloclysis.  
 
Fistuloclysis is an effective and feasible way of managing these patients and is often 
the only alternative to PN support.(4–6) Fistuloclysis seems to be an underutilised 
method of nutrition support within the South African context. The purpose of this 
study was to describe a cohort of patients where fistuloclysis has been implemented 
successfully and to investigate how hospitals in South Africa manage IF patients. In 
addition the feasibility and acceptability of fistuloclysis in the greater setting was 
investigated. There is limited South African data available with regard to nutritional 
management of patients. Gathering this data would provide a baseline from which 
change could be initiated to optimise nutritional care and improve cost effectiveness. 
The study would also provide information on training needs and equipment available 
in other institutions. It would be possible to initiate training programmes and 
protocols to develop individuals to implement fistuloclysis in their care facilities. 
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An in-depth review of the current literature on IF and the management thereof was 
undertaken and is presented in Chapter 2 of this thesis. The practical experience of 
the principle investigator with the day-to-day management of these patients gave rise 
to the objectives of this study, which are presented together with the research 
methodology in Chapter 3.  Three objectives were identified of which the results are 
presented in Chapter 4. The objectives of this study were quite diverse and therefore 
reporting of the results is done individually for each objective. Reporting of data was 
done in the form of articles, which also included a discussion of the literature and a 
conclusion. This format also necessitated referencing at the end of each article in 
Chapter 4. Chapter 5 is a discussion and conclusion section that aims to bring the 
diverse objectives together in order to draw final conclusions and make informed 
recommendations.















CHAPTER 2:  LITERATURE REVIEW
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2.1 Intestinal failure 
The concept of intestinal failure (IF) was first defined by Fleming and Remington in 
1981 as “a reduction in the functional gut mass below the minimal amount necessary 
for adequate digestion and absorption of food”.(7–9) This definition of IF has been 
revised by other authors since to include, among others, duration, stage, degree of 
impairment, underlying causes etc.(7) In 2015 The European Society for Clinical 
Nutrition and Metabolism (ESPEN) published a consensus recommendation on the 
definition and classification of IF in adults.(7) This recommendation includes a 
definition of IF, a functional and pathophysiological classification for acute and 
chronic IF and a clinical classification of chronic IF (CIF).  
 
According to the ESPEN classification, IF can be defined as the reduction of gut 
function below the minimum necessary for absorption of macronutrients and/or water 
and electrolytes, such that intravenous (IV) supplementation is required to maintain 
health and/or growth.(7)  
 
Balance study techniques, which compare nutrient requirement with nutrient 
absorption, would be the ideal way to identify and quantify IF in an individual 
patient.(7,10) These metabolic studies are however not readily available, therefore the 
need for IV replacement of nutrients and/or fluids is used as the surrogate marker for 
the diagnosis of IF.(7)  
 
Micronutrients are not included in the definition, and micronutrient deficiencies alone 
due to gut impairment are not classified as IF.(7) In situations where the absorptive 
ability of the gut is impaired, but not to the degree that IV supplementation of fluid 
and/or nutrients is required to maintain health and growth, the condition can be 
referred to as “intestinal insufficiency”.(7) 
2.1.1  Functional classification of intestinal failure 
IF has been sub-divided into three types based on the onset and expected metabolic 
impact and outcome.(7,11,12) The type of IF could predict morbidity, prognosis and 
financial implications.(13) Table 2.1 displays the functional classification of IF. 
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Table 2.1: Functional classification of intestinal failure 
Type Description Management 
Type 1 Usually self-limiting, short term and often peri-operative.
(13–15)
 
Mechanical intestinal obstruction and non-mechanical ileus.
(14)
  
Non-mechanical ileus secondary to: 
• Abdominal surgery (15% of post-operative patients).
(7)
 
• Intra-abdominal /retroperitoneal infection or inflammation. 
• Extra-abdominal causes, such as acute spinal cord injury, head injury, pneumonia, hip 
fractures and multiple organ failure.
(7,14,16) 
 
Less commonly type 1 Intestinal failure could be the result of severe enteric infection, 
inflammatory bowel disease, radiotherapy or chemotherapy.
(14)
 
 7 – 14 days Conservative management, nasogastric drainage 
and might require short term parenteral nutrition support.
(14,16) 
 
Type 2 Not self-limiting, with the exception of patients with simple intestinal fistulation where 
spontaneous closure may occur with effective nutritional and medical support.
(14) 
Sepsis and fistulation are the primary factors associated with type 2 intestinal failure in 
more than 70% of patients.
(14) 
 
Approximately 10% of patients will also have significant reduction in intestinal length at 
time of diagnosis.
(14) 




Early diagnosis and treatment of abdominal sepsis. 





o 40% - Full intestinal rehabilitation. 
o 10% - Dependency on enteral nutrition (including distal 
feeding tubes). 
o 50% - Result in Type 3 intestinal failure and requiring home 
parenteral nutrition. 
Type 3 Chronic condition in a metabolically stable patient.
(7,13,15)
  




Long-term parenteral nutrition support, often for years, with 
careful monitoring for complications.
(7,13,15)  
Chronic intestinal failure secondary to benign cause might be a 
reversible condition with 20% – 50% of patients being weaned of 
home parenteral nutrition within one to two years of starting.
(7)
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2.1.2  Pathophysiological classification of intestinal failure 
The first classification of IF based on the underlying cause was done in 1991 and 
has been developed further in the years that followed.(7,17) The term 
‘pathophysiological’ describes the primary underlying pathology that is responsible 
for the manifestation of IF.(7)  
This classification includes five primary pathologies that would result in IF:(7) (Table 
2.2) 
• Short bowel syndrome 
• Intestinal fistula 
• Intestinal dysmotility 
• Mechanical obstruction 
• Extensive small bowel mucosal disease 
 
Each of these pathologies has multiple possible underlying causes, which will be 
discussed in further detail.  
2.1.2.1  Short bowel syndrome 
Short bowel syndrome (SBS) could result from extensive surgical resection due to a 
number of aetiologies or as a result of congenital diseases of the small intestine.(7,18–
20) The normal length of the small bowel differs significantly, from 300 to 
850cm.(7,12,18,19,21,22) The absorption of carbohydrates and protein takes place mostly 
in the duodenum and jejunum, while the ileum is responsible for absorption of most 
lipids bound to bile salts.(19,20,22) The clinical manifestation of SBS is associated with 
less than 200cm of the small bowel remaining in continuity, even if the total length of 
the small bowel including the part that is bypassed or in discontinuity is of normal 
length.(7,18,22) Although length of remaining bowel correlates well with a patient’s 
degree of nutritional autonomy; the remaining anatomy, integrity and function of the 
available bowel, the underlying conditions and the ability of the bowel remnant to 
adapt is a big determining factor.(7,12,19–21) Conditions leading to SBS most commonly 
affect the jejunoileal segment and less commonly the colon.(23) SBS is the leading 
cause of type 3 IF and accounts for around 75% of adults and 50% of children 
receiving home parenteral nutrition (HPN) in Europe.(7) 
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The pathophysiological manner in which SBS causes IF is due to extensive loss of 
absorptive surface area.(7,22) Table 2.2 sets out the most frequent underlying causes 
leading to the pathophysiological condition. 
Table 2.2: Pathophysiological classification of intestinal failure with most frequent underlying 
causes. (adapted from Pironi et al. 2014 
(7)
) 
Pathophysiological classification Most frequent underlying causes 
*This list is not exhaustive of all causes 
Short Bowel Syndrome Extensive surgical resection for: 
− Mesenteric infarction 
− Crohn’s disease 
− Radiation enteritis 
− Surgical complications necessitating extensive resection 
− Intestinal volvulus 
− Abdominal trauma resulting in significant bowel resection 
− Necrotizing enterocolitis 
− Complicated intussusception 
Congenital causes: 
− Gastroschisis 
− Intestinal malformation 
− Omphalocoele 
Intestinal Fistula Inflammatory 
− Inflammatory bowel disease 
− Pancreatic disease 





Presence of foreign bodies 
Iatrogenic injury 
Intestinal dysmotility Acute 
− Post operative ileus 
− Systemic inflammatory or neurological reaction associated with critical illness 
− Ogilvie syndrome (acute colonic non-mechanical obstruction) 
Chronic intestinal pseudo-obstruction (obstructive symptoms present for at least 6 months) 
− Primary/idiopathic 
− Neuropathic: inflammatory/degenerative injury to the enteric nervous system 
− Myopathic: Damage to the smooth muscle 
− Mesenchymopathy: injury of the interstitial cells of Cajal 
− Secondary 
− Collagen vascular disease: primary systemic sclerosis, systemic lupus erythematosus, rheumatoid 
arthritis, mixed connective tissue disorders, 
− Endocrine disorders: Diabetes, hypothyroidism, hypoparathyroidism, hyperparathyroidism 
− Neurological disorders: Parkinson disease, Alzheimer disease, Hirschsprung disease 
− Medication associated: tricyclic antidepressants, anticholinergic agents, ganglionic blockers, anti-
Parkinsonian agents, clonidine, phenothiazines  
− Paraneoplastic: Central nervous system neoplasm, lung microcytoma, brochial carcinoid 
− Miscellaneous:  
− Coeliac disease 
− Infiltrative disorders (amyloidosis, lymphoma) 
− Alcohol abuse 
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− Post-infectious processes (bacterial, viral, parasitic) 
− Radiation 
− Vascular insufficiency 
− Metabolic (hypokalaemia, hypomagnesaemia) 
− Post-surgical 
− Post-organ transplant 
Mechanical Obstruction Physical obstruction 
− Intussusception 
− Gallstones 
− Foreign bodies 
− Bezoars 
− Faecal impaction 
Intrinsic bowel lesions 
− Stenosis or strictures 
− Neoplastic 
− Stenosis or strictures secondary to inflammatory bowel disease 
− Anastomotic stricture 
Extrinsic bowel lesions 
− Abdominal adhesions secondary to previous surgery or peritonitis 
− Frozen abdomen 
− Hernias 
− Peritoneal metastasis  
− Volvulus 
− Congenital bands 
Extensive Small Bowel Mucosal 
Disease 
− Microvillus atrophy 
− Intestinal Epithelial Dysplasia 
− Autoimmune enteropathy 
− Intestinal lymphangectasia 
− Protein loosing enteropathy 
− Crohn’s disease 
− Coeliac disease 
− Radiation enteritis 
− Chemotherapy related enteritis 
− Congenital diseases 
 
The three most common types of intestinal resections resulting in SBS are 
jejunoileal, jejunocolic and jejunostomy.(11)  
2.1.2.1.1  Jejunoileal anastomosis 
With a jejunoileal anastomosis, a portion of the jejunum and often a part of the ileum 
have been resected and the remaining parts are anastomosed.(11) Patients retain the 
terminal ileum, ileocaecal valve and colon.(11) The structural adaptation of the ileum 
is far greater than that of the jejunum and therefore proximal bowel resections are 
better tolerated.(19) Patients rarely present with major nutrient or electrolyte 
deficiencies because the remaining ileum and colon will compensate adequately for 
the resected portion of the bowel.(11,19) The tight junctions between enterocytes in the 
ileum are far less permeable than that of the jejunum therefore less water enters the 
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lumen of the ileum following the ingestion of a hyperosmotic meal.(11) Furthermore 
the colon has great water and electrolyte absorption capability.(11) Under normal 
conditions the colon absorbs approximately 1,9 litres of water per day, but has the 
potential to absorb up to 5 litres of fluid per day.(11,21) The colon can also utilise 
maldigested carbohydrates and proteins through anaerobic bacterial fermentation 
providing an additional source of nutrition.(11,12,21,22) Patients with colon continuity can 
salvage up to 1 000 additional calories per day from unabsorbed carbohydrates.(21) 
 
Most patients with jejunoileal anastomosis have an intact duodenum and part of the 
jejunum, therefore site-specific digestion is not compromised and development of 
nutrient deficiency is relatively infrequent.(11)  
 
Jejunal resection could result in decreased secretion of regulatory hormones by the 
jejunal cells.(11) This could lead to gastric hypersecretion in the acute postoperative 
stage due to loss of cholecystokinin (CCK) and secretin feedback inhibition 
mechanisms.(11,22) Gastric hypersecretion could lead to a decrease in the pH of the 
proximal intestine with denaturation of pancreatic enzymes and impaired 
digestion.(11) This phase is usually self-limiting, lasting a few weeks to months, and 
can be treated successfully with proton pump inhibitors (PPI) or an H2 antagonist.
(11) 
2.1.2.1.2  Jejunalcolic anastomosis 
Ileal resections generally result in more complicated disease owing to the decreased 
adaptive capacity of the jejunum.(11,24) Patients with ileal resections are more likely to 
present with diarrhoea due to the decreased capacity of the jejunum to absorb water 
and the added strain on the colon.(11) If the colon is also partly resected, in addition 
to the ileum, diarrhoea symptoms could be worse.(11) With ileal resection some of the 
specific functions of the ileum will be impaired, such as Vitamin B12 absorption and 
bile salt re-absorption.(11,19,20) Patients who undergo distal ileum resection (>60cm) 
should typically be supplemented intramuscularly (IM) with Vitamin B12.
(11,21,22) Ileal 
resection of >100cm results in a net loss of bile salts and can lead to fat 
malabsorption, fat-soluble vitamin deficiencies, steatorrhea and choleretic 
diarrhoea.(11,19–22) In balance studies investigating the result of bowel resection on 
macronutrient absorption it has been shown that, with a bowel remnant of between 
30 and 100cm post duodenal-jejunal (DJ) flexure, carbohydrate and lipid absorption 
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was decreased to 75% and 50% respectively while protein absorption remained high 
at 80%.(19)   
 
Hormonal mediators of digestion synthesised by enteroendocrine cells in the ileum 
and colon are also affected by resection.(11) Glucagon-like peptide – 1 (GLP-1), 
Glucagon-like peptide – 2 (GLP-2) and Protein YY (PYY) are up-regulated following 
ileal resection if the colon remains in continuity.(11,22,25) GLP-1 and PYY both 
suppress gastric emptying, gastric acid secretion and small bowel motility.(11,22,25) 
Therefore patients with ileal resection, but colon remaining in continuity, have normal 
gastric emptying and transit time.(11,22) Gastric acid hypersecretion is less severe 
after ileal resection than following jejunal resection.(11,22) An up-regulation of GLP-2, 
an intestinotrophic peptide hormone, leads to increased villus height and crypt cell 
proliferation and thus mediates intestinal adaptation following resection.(11) 
2.1.2.1.3  Jejunostomy 
Patients with an end-jejunostomy, i.e. ileum and colon resected, have the most 
profound malabsorptive complications.(11) These patients have the same loss of 
water absorptive capacity as patients with ileum resection, but also lack the water- 
and electrolyte-absorption ability and energy salvaging capabilities of the 
colon.(11,12,21,22)  
 
Patients with less than 100cm of remnant bowel tend to require long-term PN since 
their stoma output of fluid and salts exceed their intake owing to lack of gastric 
secretion reabsorption.(11) Due to the extent of bowel resection, these patients also 
lack the specific absorption sites for Vitamin B12 and bile salts.
(11,19,20) Other nutrients 
that are absorbed in the distal small intestine or colon, like magnesium, will similarly 
be affected and give rise to the hypomagnesaemia, which is, despite oral 
magnesium supplementation often observed in these patients.(11) 
 
Due to the lack of colon, patients with an end-jejunostomy do not experience up-
regulation of GLP-1, GLP-2 and PYY and experience increased gastric emptying and 
intestinal transit.(11) This leads to decreased contact time between the nutrients and 
the mucosa for digestion and absorption.(11) 
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All SBS patients will require PN support in the immediate postoperative phase to 
maintain nutritional status.(23) Some patients can be weaned off PN while others 
might require long-term PN support. Patients with a very short remnant bowel and 
patients absorbing less than a third of their intake typically require long-term PN 
support.  
 
SBS with permanent PN dependence is strongly related to a small bowel length of 
<50cm post duodenum and to the absence of ileum and/or colon in continuity.(26) 
Values separating transient and permanent IF differ according to anatomy and are 
100cm for an end-enterostomy, 65cm for a jejunocolic anastomosis and 30cm for a 
jejunoileocolic anastomosis.(26) PN dependence at five years is around 45%.(26)  
 
Patients with SBS can be classified according to their PN or IV support needs as 
intestinal insufficiency or IF.(23) Patients with intestinal insufficiency will be able to 
wean off PN, skip PN days or not require PN support at all and be able to maintain 
nutritional status through hyperphagia.(23) Hyperphagia is defined as a >1,5-fold 
increase in caloric requirements over the resting energy expenditure.(23)  
2.1.2.1.4  Bowel adaptation 
Extensive intestinal resection is followed by three phases of adaptation.(27) 
1. The acute phase: This phase starts immediately following resection and last 
for a period of approximately four weeks.(22,27) During this stage the intestinal 
mucosa and peristalsis adjust to the new environment.(27) 
2. The adaptation phase: Lasts for one to two years. Patients usually require PN 
or enteral nutrition support until adequate intestinal adaptation has occurred to 
maintain nutritional status without artificial nutritional support.(22,27) 
3. The maintenance phase: During this phase nutrition treatment should be 
individualised according to patient requirements and deficiencies.(22,27) 
 
Bowel adaptation usually occurs within the first two years following the last surgical 
intervention.(20,22,23) The degree of adaptation is related to the extent of the resection, 
as well as the anatomy of the remnant bowel.(20,24,28) Structural and functional 
changes occur in the remnant bowel which improves nutrient and fluid 
absorption.(20,22,24,28) Structural changes include hyperplasia, angiogenesis, bowel 
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dilation and bowel elongation.(20,28) A study by Joly et al. showed a 35% increase in 
crypt depth and a 22% increase in number of cells/crypt in the colon of 12 patients 
with jejunocolic anastomosis.(28) Functional changes include increased expression of 
transporter proteins and exchangers involved in nutrient and electrolyte absorption, 
as well as an accelerated maturation of enterocytes.(20,28) This leads to increased 
digestive and absorptive capacity of the remnant bowel.(28) Another functional 
adaptation is reduced transit time, allowing for slower transit of nutrients through the 
intestine and thus longer contact time for absorption.(28) Patients with ileal resection 
and colon in continuity have higher plasma levels of PYY that delay gastric emptying 
and increase transit time.(28) A publication by Nightingale et al. states that there is no 
evidence of any functional or structural adaptation in patients with end-
jejunostomies, therefore change in nutritional and fluid needs are unlikely with 
time.(25) 
 
Factors that play a role in intestinal adaptation include the anatomic features, enteral 
stimulation, hormones and growth factors.(28,29) Enteral stimulation is required to 
maintain gut integrity.(28) In the absence of luminal nutrients, mucosal atrophy and a 
decrease in enzyme and nutrient transporter activity occur, even with adequate 
calorie and protein provision via PN support.(28,30) This atrophy is reversible with the 
re-introduction of enteral nutrition.(28) Luminal nutrients enhance bowel adaptation 
following resection and increased nutrient complexity is associated with improved 
adaptation.(20,28,29) Individual nutrients have also been identified to promote 
adaptation.(28) Fat seems to improve bowel adaptation and has been associated with 
significantly increased bowel weight and villus height in animal studies.(28) Long-
chain triglycerides (LCT) are superior to medium chain triglycerides (MCT) in 
promoting hyperplasia following bowel resection.(28,29) Short chain fatty acids (SCFA) 
have also been shown to enhance intestinal adaptation, although data are 
sparse.(28,29) 
 
Glutamine is a primary fuel source for enterocytes and has been shown to 
counteract PN-induced intestinal atrophy and improve bowel adaptation when 
supplemented in PN.(28,29) Glutamine administered via the enteral route has not 
shown a positive effect on structural or functional bowel adaptation.(22,28) Glutamine 
and growth hormone (GH) has shown some efficacy.(28)  
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In terms of intestinotrophic factors, recombinant human GH (somatropin) and GLP-2 
analog, teduglutide, are approved for clinical use in adult patients with SBS.(20,28) 
GLP-2 is an intestinotrophic peptide which is secreted by the L cells in the terminal 
ileum and colon in response to the presence of nutrients in the gut lumen and 
induces structural and functional adaptations in the small bowel.(20,22) 
 
According to consensus data most of the adaptation occurs within the first two years 
following resection, although some studies have suggested significant improvement 
beyond two-years.(28) Adaptation after two years is uncommon and limited to a 
maximum improvement of 5 to 10 % in absorptive capacity.(23) Citrulline is a non-
essential amino acid produced exclusively by enterocyte. Plasma levels of citrulline 
act as a functional marker of intestinal function and levels of <20μmol/L have been 
found to correlate with PN dependence at two years post resection.(20,22,24) Inability to 
wean a patient off PN or IV support after two years has a 95% likelihood of 
permanent IF.(20,23,26) 
2.1.2.1.5  Short bowel syndrome complications 
Complications related to bowel resection can extend to tissues and organ systems 
beyond the gastrointestinal tract.(11) 
 
Ileum resections of more than 60 to 100cm usually result in the enteric loss of bile 
acids exceeding the synthetic capacity, resulting in a decline in the bile acid pool.(27)  
Bile acid malabsorption resulting in bile salt deficiency prevents solubilisation and 
absorption of fatty acids and results in steatorrhea, malnutrition and fat-soluble 
vitamin deficiency.(11,27,30) Decreases in the bile salt concentration of bile acids 
accompanied by increased secretion of cholesterol into bile, lead to the formation of 
lithogenetic bile which in turn leads to an increased incidence of gallstones.(19,25) 
Drugs that are excreted via bile have their action prolonged by the enterohepatic 
circulation; therefore disruption of this circulation impacts on the bioavailability of 
drugs.(31) These drugs include mycophenolic acid, warfarin, digoxin, oral 
contraceptives, cyclosporine, tacrolimus and statins.(31) Malabsorption of fat-soluble 
vitamins also affects the absorption of the drugs that interact with them, for instance 
warfarin, hydrocortisone, estrogen, other sex hormones and cyclosporine.(31) This 
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might become problematic in the setting where patients are dependent on 
immunosuppressive or oral contraceptive therapy.(31)   
 
Unabsorbed fatty acids bind to intraluminal calcium.(11,21,22) Calcium would under 
normal conditions bind to oxalate and be excreted in the stool.(11,21,22) Furthermore 
the presence of bile salts in the colon promotes the absorption of oxalate in the 
colon.(19) Owing to the calcium fatty-acid soaps that form there is a lot of free oxalate 
available for absorption in the colon.(11,21) Oxalate is excreted by the kidneys and the 
increased load could lead to the formation of oxalate kidney stones.(11,21,25) An 
estimated 60% of patients with SBS develop hyperoxaluria while up to 25% of 
patients with jejunocolic anastomosis and <200cm of small bowel remnant present 
with oxalate kidney stones.(11,25) Patients with ileal resections and colon in continuity 
should follow a diet low in oxalate and increase calcium intake.(11,27) The addition of 
cholestyramine to bind bile salts in the colon can also be considered.(19) 
 
Another consequence of bile salt malabsorption and a diminished bile acid pool is 
that insufficiently solubilised cholesterol supersaturates bile and leads to cholesterol 
gallstone formation.(11) High levels of bile salts in the colon lead to solubilisation of 
unconjugated bilirubin and promote the absorption thereof, this leads to a three to 
10-fold increase in the bilirubin level in the bile of patients with ileal resections and 
predisposes them to the formation of pigment gallstones.(27) Other contributing 
factors to gallstone formation are decreased gallbladder contractility and 
hypersecretion of mucin, a nucleation-promoting protein.(11)  Gallstones occur in 25 to 
45% of SBS patients with cholecystitis developing in up to 10% of patients. A shorter 
intestinal remnant, Crohn’s disease, absence of an ileocaecal valve and long-term 
PN dependence correlate with higher risk of developing gallstones. Colon continuity 
plays no role in the prevalence of gallstone formation.(11) 
 
Although the colon has a much smaller role in terms of absorption compared to the 
small intestine it has several carrier-mediated transport systems used for colonic 
absorption of pharmacological agents. Furthermore, drugs that are not completely 
absorbed in the small intestine might continue to be absorbed in the colon. Rectal 
delivery of drugs by means of suppositories is an alternative route for the effective 
administration and absorption of drugs. When a patient has no colon the absorption 
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site for some drugs are removed. One affected group is drugs with an extended 
release like β-blockers and antihypertensives.(31)   
 
Drugs delivered in pill or capsule form have the potential to cause obstruction of 
stomas or strictures if they are not dissolved fully. Particular attention should be paid 
to erosive drugs that can cause damage to the intestine just proximal to the stoma or 
stricture if they get stuck. Consideration should be given to change to drugs in liquid 
formulation, intramuscular formulations or intranasal formulations.(31)  
2.1.2.2  High-output fistulae 
A fistula is defined as an abnormal communication between two epithelial-lined 
surfaces.(2,7,32–35) 
 
There are several ways to classify fistulae, which may be based on the anatomy, 
physiology or aetiology.(33–37) For the purpose of this review, we will focus on the 
three most common classifications.  
 
Anatomically a fistula is classified according to the segment of gut it originates from 
and the organs involved.(7,34,38) A gastrointestinal fistula can develop between the gut 
and the skin (enterocutaneous), referred to as an external fistula, or between the gut 
and another adjacent viscus (enteroenteric), referred to as an internal 
fistula.(33,36,37,39) The high pressure organ from which the fistulae arise is named 
first.(38)  
 
The physiological classification of fistulae is based on the output.(7,36,38,40) Less than 
200ml effluent per day is considered low output while 200 to 500ml per day is 
classified as moderate output.(7,34,36,37,40) A fistula effluent of more than 500ml per 
day in the fasted state is considered as a high-output fistula and is associated with a 
higher morbidity and mortality.(7,32,34,36,40) Edmunds et al. demonstrated a mortality 
rate of 54% in patients with high output fistulae while patients with low-output fistulae 
had a mortality rate of 16%. This was supported by Levy et al., who demonstrated a 
mortality rate of 50% and 26% respectively in patients with high- and low-output 
fistulae.(36)  
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Fistulae can be classified as primary (type 1) or secondary (type 2) according to the 
aetiology.(33,39) Primary fistulae develop as a result of an underlying disease, while 
secondary fistulae are the result of insult or injury to a previously healthy bowel.(33,39) 
Table 2.2 lists the possible causes that could result in fistulae. Table 2.3 lists 
primary and secondary fistulae causes. An estimated 75% to 85% of fistulae arise 
from surgical complications.(7,32,35–37,41–43) These usually present five to 10 days after 
surgical intervention.(2,7,32) The remaining 15% to 25% of complications arise from 
underlying pathology.(7,42,43) 
Crohn’s disease is a major contributor to secondary fistula development.(7,32,42) An 
estimated 40% of patients with Crohn’s disease will develop a fistula in the course of 
their illness.(32) In developing countries spontaneous fistulisation might occur in the 
presence of complicated infectious diseases such as abdominal tuberculosis, 
amoebiasis and typhoid.(42) 
Table 2.3: Causes and risk factors for primary and secondary fistulae
(33,39)
 











− Anastomotic Failure 
− Breakdown of repaired enterotomy 
− Iatrogenic Injury 
− Peritonitis 
− Trauma 
− Prosthetic Mesh 
− Hepatic/renal insufficiency 
 
An enteroatmospheric fistula (EAF) is a sub-set of fistulae that arise in the setting of 
an open abdomen with exposed viscera.(34,35,40,44) Patients with open abdomens 
present a high risk for the development of fistulae with an incidence of 5 to 19%.(40) 
The longer the abdomen remains open with a temporary dressing the higher the 
likelihood of developing an EAF.(40) This type of fistula is almost exclusively 
described in traumatically injured or critically ill patients.(44) This patient population 
present with a unique risk for fistulisation due to intentional or unintentional bowel 
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injury, intra-abdominal infections and decompression for abdominal compartment 
syndrome.(44)  
 
The pathophysiological manner in which fistulae cause IF is the enteric content being 
lost through a proximal opening or by bypassing a significant segment of gut in the 
case of internal enteroenteric fistulae.(7,33,38) This effectively leads to a situation of 
‘short bowel’.(7,42)  
 
Fistula closure can happen spontaneously or by surgical intervention.(32,42) Generally 
patients presenting with type 1 intestinal fistulae will require resection of the 
diseased segment of bowel, while type 2 fistulae have the potential to close 
spontaneously.(39) Dense adhesions form in the abdomen following major abdominal 
surgery.(42) This is usually at it’s most severe between three weeks and three months 
following surgery.(42) Attempts to re-enter the abdomen during this period could result 
in further complications.(42) It is therefore recommended to postpone surgery, which 
also allows time for correction of metabolic and nutritional derangements.(42)  
 
Several factors impact on the likelihood of spontaneous closure of a fistula, as 
indicated in Table 2.4 (32,36,39,42) 
Table 2.4: Factors that impair spontaneous fistulae closure
(32,36,37,39,43)
 
− Age >65 years 
− Malnutrition and transferrin <200mg/dL 
− Discontinuity of bowel ends 
− Distal obstruction 
− Chronic abscess 
− Malignancy involving the gastro-intestinal tract 
− Organ involved: stomach, duodenum, ileum 
− Fistula duration: > 4 – 6 weeks 
− Fistula output >500ml 
− Etiology: Inflammatory bowel disease, malignancy, radiation enteritis 
− Co-morbidities: sepsis, diabetes, renal failure, current chemotherapy or radiation therapy or 
corticosteroid treatment 
− Fistula presentation: 
− External, complex, multiple or end fistula 
− Fistula tract <2cm or defect >1cm 
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− Eversion of mucosa or distal occlusion 
− Poor or diseased adjacent bowel 
− Presence of abscess or foreign body 
− Presence of abdominal wall defect 
− Management errors: 
− Failure to diagnose an anastomotic leak 
− Delay in surgical exploration 
− Attempt to restore intestinal continuity too early 
− Failure to initiate nutrition support 
 
2.1.2.2.1  Nutritional management of high-output fistulae 
Up to 70% of patients with fistulae present with malnutrition.(32,43) The presence of 
malnutrition can be defined as a 10% loss of body weight and the presence of 
hypoproteinemia.(43) In a study by Fazio et al., albumin levels of >35g/l were 
associated with no mortality, while patients with serum albumin <25g/l had a 
mortality rate of 42%.(43) This has been confirmed by Visschers et al. in 2008 
demonstrating no mortality in patients with pre-operative serum albumin levels 
>25g/l, while 32% of patients with a level <25g/l died.(45) Serum transferrin levels also 
have a strong association with mortality and fistula closure.(43,46)  
 
In a study by Chapman et al., there was a dramatic decrease in mortality associated 
with a calorie intake of >1 500kCal/day.(41) Mortality decreased from 58% to 16%.(41) 
Furthermore, patients who, were able to maintain optimal nutrition, defined as >3 
000kCal/day, had an even lower mortality rate, 12%, and fistula closure rates 
approaching 90%.(41) The majority of these patients were maintained on enteral 
nutrition.(41) Enteral nutrition support is the preferred route of nutrition support, unless 
it increases fistula output dramatically or causes increased abdominal pain or 
exacerbates diarrhoea.(8,32,41) Enteral nutrition as opposed to PN has several 
advantages, in particular with regard to improved intestinal barrier function and 
reduced rate of infectious complications.(2,4) In the patient with IF the part of intestine 
deprived of nutrition for an extended period of time will have marked atrophy, 
resulting in disparity between bowel ends and poor quality tissue for anastomosis 
when restorative surgery is performed.(4) Bowel absorptive capacity should be 
sufficient for successful implementation of enteral nutrition support.(33) Patients with 
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fistulae should be able to tolerate polymeric enteral formula, unless they have less 
than 120cm of bowel left, have documented intolerance to polymeric feed or are 
experiencing high fistula output.(40) In that case patients should be changed to a 
semi-elemental or elemental enteral product.(40) The literature suggests absolute 
contra-indications to enteral nutrition include bowel discontinuity or insufficient bowel 
length, usually <75cm.(35,40) 
 
Patients should be allowed to take food or fluids orally if they wish to do so for the 
psychological benefits derived from this.(40) Oral intake should be abandoned if fistula 
output increases to unmanageable levels in terms of volume and electrolyte 
abnormalities.(40) Oral intake of large volumes of fluid can stimulate increased losses 
from the fistula together with high losses of electrolytes.(33) The type of fluid is 
important and patients should be encouraged to take isotonic fluids orally.(33,42) The 
nutritional requirements of patients with high- or low-output fistulae are displayed in 
Table 2.5.  
Table 2.5: Nutritional Requirements
(32,35,36,40,41,43)
 





1 – 1,5g/kg RDA 
High risk for VitB12, Zn, Mg 
and selenium deficiency 
High output Gastro-
intestinal fistula 
1,5x REE or 
30kCal/kg/day TE 
1,5 – 2g/kg  2 x DRI of vitamins and 
trace elements. 5 x DRI for 
Vit C and Zn 
High risk for VitB12, Zn, Mg 
and selenium deficiency 
2.1.2.2.2  Pharmacological management of high output-fistulae 
Drug therapy plays an important role in the management of high-output fistulae and 
SBS. It can be divided into antimotility or antisecretory drugs.(33,41,42)  
Antimotility drugs such as loperamide and codeine phosphate can decrease sodium 
losses by approximately 30%.(25,33,35) Loperamide should be taken 30 minutes prior 
to meals.(20,41)  
 
Antisecretory drugs include PPI and somatostatin or octreotide.(36,41) The disturbance 
in the CCK and secretin feedback mechanism in patients with entero-cutaneous 
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fistula may result in increased gastric hypersecretion.(41) PPIs can be administered to 
reduce gastric secretions.(33,36) Somatostatin or somatostatin analogues might be 
helpful in decreasing gastric secretions and output.(33,35,36,42) The effectiveness of 
somatostatin is very limited owing to its extremely short half-life, approximately one 
to three minutes.(34,42,43) The somatostatin analogue, octreotide, has a longer half-life 
of two hours and has shown promise in reducing fistula output by 40% to 
93%.(34,40,42,43) Octreotide can however negatively affect immune function due to GH 
inhibition.(34,40) Studies demonstrating an improvement in fistula output with the use 
of octreotide have failed to show any benefit in terms of efficacy relating to fistula 
closure.(36,41,43)  
 
Although reduction in fistula output by means of pharmacotherapy has not shown 
any benefit in the closure of fistulae, it does provide other advantages in terms of 
electrolyte imbalances, improved wound care and higher likelihood of tolerating 
enteral or oral nutrition.(35,40,41)  
 
Pharmacotherapy aimed at reducing stoma or fistula output could potentially impact 
on the absorption of other pharmacological formulations.(31) PPIs and H2 receptor 
antagonists can increase or decrease the bioavailability of other drugs.(31) An 
increase in the pH of the stomach impairs the absorption of drugs that are weak 
bases, for example antifungals (ketoconazole, itraconozole, and griseofulvin), 
antiretrovirals (atazanavir, cefpodoxime, enoxacin and dipyridamole), Vitamin B12 
and iron salts.(31) On the other hand an increase in stomach pH increases the 
bioavailability of digoxin, nifedipine and alendronate.(31) If PPIs are used, alternative 
administration of the affected drugs should be considered.(31)  
2.1.2.3  Intestinal dysmotility 
The term intestinal dysmotility refers to the presence of a disorder that impairs the 
propulsion of gut content in the absence of an obstruction. It can be further divided 
into loco-regional, indicating that an isolated segment is affected (eg. Achalasia and 
gastroparesis) or multi-regional, involving more than one part of the gastrointestinal 
tract, often the small intestine. Intestinal dysmotility can present as type 1 IF in the 
case of acute postoperative ileus or critical illness-associated ileus. Dysmotility often 
presents das a result of systemic or intra-abdominal inflammation as type 2 IF. CIF, 
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associated with dysmotility, is referred to as chronic intestinal pseudo-obstruction 
(CIPO) with the ‘pseudo’ indicating the absence of an occluding lesion. CIPO can be 
divided into congenital causes, which are more prevalent in children, or acquired 
causes, with a higher prevalence in adults.(7) Table 2.2 indicates the possible causes 
of intestinal dysmotility.  
Histologically CIPO can be divided into three categories:(7) 
− Neuropathies involving the enteric nervous system and/or autonomic nervous 
system 
− Myopathies involving the smooth muscle 
− Mesenchymopathies involving the interstitial cells of Cajal. 
 
The primary pathophysiology in intestinal dysmotility that gives rise to IF is the 
intolerance to oral or enteral nutrition resulting in inadequate nutrient intake. 
Generally the mucosal surface is preserved. Secondary mechanisms that play a part 
are the malabsorption of nutrients due to bacterial overgrowth in stagnant bowel 
loops as well as increased intestinal losses of fluids and electrolytes due to 
increased secretions in dilated bowel loops. Intestinal resection in an attempt to 
eliminate symptoms might also play a role.(7) 
2.1.2.4  Mechanical obstruction 
Mechanical obstruction refers to a physical abnormality occluding the intestine. This 
could be intraluminal (eg. foreign bodies), intrinsic (eg. stenosis), or extrinsic (eg. 
frozen abdomen). Furthermore these might be of benign or malignant origin. 
Possible causes of mechanical obstruction are listed in Table 2.2. 
It could present as a type 1 IF which presents acutely and resolves within days with 
conservative management or surgery. It may also present as a type 2 or 3 IF with a 
prolonged course.(7)  
 
The pathophysiological mechanism of IF due to mechanical obstruction is the 
spontaneous or prescribed ceasing of oral intake. Secondary to that, increased 
intestinal losses of fluids and electrolytes into distended bowel loops as well as due 
to vomiting or increased nasogastric drainage adds to the manifestation of IF.(7) 
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2.1.2.5  Extensive small bowel mucosal disease 
Extensive small bowel mucosal disease refers to a condition where there is intact or 
almost intact, but inefficient mucosal surface. There is a reduction in nutrient 
absorption and/or an increase in nutrient loss via the mucosa to the point where the 
nutritional needs cannot be met.(7) Possible causative diseases are listed in Table 
2.2.  
2.1.3  Clinical classification of intestinal failure 
The ESPEN expert committee involved in the development of the consensus 
guidelines on IF agreed on the need for a clinical classification of IF to facilitate 
communication among healthcare professionals as well as for use in clinical practice 
and standardisation of research. There were no published data available to use as a 
basis and therefore the classification was based on the experience of the ESPEN 
expert panel. This classification only refers to type 3 CIF and is based on the 
average daily IV energy and fluid supplementation requirements of a patient, 
categorised into 16 subtypes of IF.(7) Table 2.6 illustrates the clinical classification of 
chronic IF. 






(kCal/kg Body Weight 
b
Volume of IV fluid supplementation 
≤ 1000 
(1) 
1001 – 2000 
(2) 




0 (A) A1 A2 A3 A4 
1 – 10 (B) B1 B2 B3 B4 
11 – 20 (C) C1 C2 C3 C4 
> 20 (D) D1 D2 D3 D4 
a 
Calculated as daily mean of the total energy infused per week = (energy per day of infusion x number of infusions per week)/7 
b
 Calculated as daily mean of the total volume infused per week = (volume per day of infusion x number of infusions per 
week)/7 
2.2 Prevalence and prognosis of intestinal failure 
Type 1 IF is a relatively common occurrence, a 2010 United Kingdom (UK) survey 
showed that 93% of in-patients to whom PN was administered received it for <30 
days.(15) The majority of these patients required nutrition support secondary to 
postsurgical complications.(15) The incidence of postoperative ileus can be as high as 
15% following intestinal resection.(16)  
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Type 2 and type 3 IF is less common. Surveys of prolonged PN use in hospitals in 
England have suggested that the incidence of type 2 IF may be as high as 18 per 
million population per year. This estimate is based on patients requiring PN for at 
least 14 days.(14) A British survey reported 624 adult patients with IF receiving HPN 
in 2010.(15)  
 
In the UK, Crohn’s disease, intestinal ischemia and surgical complications are the 
major contributing pathologies for patients requiring long-term or HPN support. Data 
from other European countries and Canada show similar results. The main aetiology 
for HPN in the United States of America (USA) and Japan is cancer; contributing 
42% and 40% respectively. This includes patients with malignant small bowel 
obstruction, SBS and high-output fistulae due to malignancy.(15)  
 
The incidence and prevalence of SBS in adults is not well described owing to the 
lack of a reliable patient database. Approximately 40 000 adults received HPN or 
home IV support in the USA in 1992, of these 10 000 had a diagnosis consistent with 
SBS. In Europe patients receiving HPN are estimated at two to three per million with 
four per million receiving home IV support. Approximately 35% of these patients had 
a diagnosis consistent with SBS, therefore the estimated prevalence of SBS in 
Europe is around 1,4 per million. SBS is generally associated with decreased 
survival. Survival of adults with non-malignant related SBS is 94% at one year, 70% 
at five years and 52% at 10 years. Patients with SBS related to radiation for 
abdominal or pelvic malignancies were slightly lower with 83% at one year and 68% 
at five years.(23)  
 
Several risk factors correlated with a poor prognosis in non-malignant SBS. These 
include:(23,26) 
• Gastro-intestinal anatomy with an end-jejunostomy.  
• Remnant bowel length <50cm. 
• Primary diagnosis of arterial mesenteric infarction. 
• History of cancer. 
• Age >60 years. 
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Death related to HPN increases with duration of PN support but accounts for only 5-
20% of deaths in this patient group.(23)  
 
CIPO-associated IF accounts for 20% of adults and children receiving HPN. The 
complete recovery rates from CIPO is much lower than that of SBS with only 25–
50% reported in adults and 25–38% reported in children. Five-year survival for adults 
requiring HPN secondary to CIPO is 78%.(7) 
 
The prognosis of enterocutaneous fistula is dependent on the patient characteristics, 
nutritional status, fistula characteristics and other co-morbidities.  
EAF have a mortality rate of 36–64%, much higher than that of enterocutaneous 
fistulae. Enterocutaneous fistulae with an intact abdominal wall have a spontaneous 
closure rate of 50–80%, while EAF require surgical intervention in the majority of 
cases.(44) 
 
Extensive small bowel mucosal disease causes 25% of CIF cases in children and 
5% in adults. In adults the likelihood of reversal of CIF due to extensive small bowel 
mucosal disease is rare.(7)  
 
In-hospital mortality associated with acute IF is as high as 13%.(16) Patients with CIF 
secondary to benign causes have a good prognosis with five-year survival rates of 
80% in adults and 90% in children.(7) The outcome of these patients, in terms of 
rehabilitative ability, treatment-related morbidity and mortality and survival, are 
however largely dependent on the care and support from an expert specialist team.(7)  
 
In-hospital mortality resulting from type 2 IF is between 9,6% to 13%. Mortality in this 
patient group were mostly attributable to underlying sepsis, which could be from an 
intra-abdominal source but also from extra-abdominal sources such as bone, 
cardiac, central nervous system and central line-associated infections.(7) 
2.3 Intestinal failure associated liver disease 
Although PN is a life-saving route of nutrition support for patients with IF, it is 
associated with several side effects, hepatobiliary dysfunction being one of the most 
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prevalent and severe complications.(27) Liver decompensation associated with long-
term PN support is referred to as intestinal failure-associated liver disease 
(IFALD).(27) This includes biochemical (increased liver enzymes) and histological 
(steatosis, cholestasis and cirrhosis) alterations.(18) 
 
IFALD is defined as persistently elevated serum transaminases, 1,5 times the upper 
limit of normal in the presence of SBS. It is often difficult to determine whether the 
liver dysfunction is a consequence of SBS, nutrition therapy or drug therapy.(27) 
 
Three types of hepatobiliary disorders are associated with IFALD:(27,47) 
• Steatosis 
• Cholestasis 
• Gallbladder stones or sludge 
Steatosis occurs predominantly in adults and is usually benign, and patients remain 
asymptomatic. It presents with mild to moderate elevation of aminotransferase (ALT 
and AST) levels and with a lesser degree of elevation in alkaline phosphatase (ALP) 
and bilirubin. Typical onset occurs after two weeks of PN therapy and may even 
return to normal with continuation of PN therapy. Progression to fibrosis and cirrhosis 
might be a consideration in patients receiving long-term PN support.(47) 
 
Cholestasis predominantly occurs in children, but might also be a complication in 
adult patients receiving long-term PN support. It is characterised by elevations in 
ALP, gammaglutamyl transpeptidase (GGT) and conjugated bilirubin with or without 
clinical jaundice. Alanine aminotransferase (ALT) and Aspartate aminotransferase 
(AST) might also be elevated. Elevated conjugated bilirubin is considered the prime 
indicator for cholestasis. Cholestasis is a serious complication, which may progress 
to cirrhosis and liver failure. If PN is stopped before irreversible hepatic damage 
occurs, complete recovery is expected and levels usually return to normal within one 
week to two months.(47) 
 
Gallbladder stasis might lead to development of gallstones or gallbladder sludge with 
subsequent cholecystitis. This condition occurs in both paediatric and adult patients 
receiving parenteral nutrition support.(47) 
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Approximately 25 to 100% of adults and children requiring PN support present with 
elevated liver functions tests.(27)  
2.3.1  Etiology of intestinal failure associated liver disease 
2.3.1.1  Duration of parenteral nutrition support 
The prevalence of IFALD increase with the duration of PN support.(27) Biochemical 
and histological complications can develop as early as four weeks after starting PN 
with more serious complications developing later in the treatment, usually after 16 
weeks of therapy.(18) 
 
An estimated 65% of patients presented with chronic cholestasis after six months of 
PN support while 37% of patients presented with complicated liver disease following 
17 months of PN support. IFALD prevalence was 26% at two years and 50% at six 
years while 22% of deaths were associated with end-stage liver disease.(27) 
2.3.1.2  Length of bowel remnant 
The risk of cholelithiasis increases significantly with a bowel remnant of less than 
120cm and if the terminal ileum has been resected.(27) A bowel remnant of less than 
50cm is associated with a significant increased risk of IFALD.(47,48) SBS is associated 
with disruption of enterohepatic circulation and alterations in bile acid metabolism 
and excretion predisposing patients to the development of IFALD.(47) 
2.3.1.3  Bacterial overgrowth 
The reduced enterohepatic circulation due to SBS and intestinal stasis occurring 
secondarily to motility disorders such as CIPO could lead to bacterial overgrowth in 
the small intestine. Bacterial overgrowth occurs when bacteria normally found in the 
colon and lower small bowel populates the upper small intestine. It is thought that 
these bacteria could potentially produce hepatotoxins, which could cause hepatic 
injury. Bacterial overgrowth may also contribute to cholestasis by promoting 
deconjugation of bile acids, preventing their reabsorption.(47) 
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2.3.1.4  Lack of enteral nutrition 
Patients who are unable to tolerate any enteral nutrition are more prone to 
developing IFALD than those who can tolerate even very small amounts. Lack of 
enteral stimulation reduces hepatocellular bile acid and bile secretion and reduced 
gallbladder contractility. Biliary sludge could develop as a result of reduced activity. 
Fasting could also reduce the size of the bile salt pool and bile formation, which 
contributes to the problem. Reduced secretion of gastrointestinal hormones could 
also lead to intestinal stasis and subsequent bacterial overgrowth.(47) 
2.3.1.5  Recurrent episodes of sepsis 
Bacterial and fungal sepsis correlates strongly with cholestasis. Sepsis causes 
systemic inflammation of the liver due to the release of pro-inflammatory cytokines 
which result in altered membrane function of the bile canaliculi and subsequent 
reduced bile flow.(47) 
2.3.1.6  Toxic components of parenteral nutrition 
Manganese is excreted in the bile and therefore the toxic effect is more pronounced 
in patients with cholestasis. This is supported by recent evidence showing 
manganese toxicity in patients on long-term PN support. (27)  
2.3.1.7  Nutritional composition of parenteral nutrition  
Studies have shown that the development of hepatic steatosis is primarily due to 
excessive calorie provision.  
Provision of excessive calories is thought to promote hepatic fat deposition by 
stimulating insulin release, which promotes lipogenesis and inhibits fatty acid 
oxidation.(47) 
2.3.1.7.1  Dextrose 
PN formulations that contain little or no fat are thought to promote the development 
of steatosis. Excessive amounts of carbohydrates will be deposited in the liver as fat, 
which could lead to the development of steatosis. Also, formulations containing little 
or no fat could lead to the development of essential fatty acid deficiency which could 
impair lipoprotein formation and triglyceride secretion, and result in steatosis.(47) 
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2.3.1.7.2  Amino acids 
Taurine deficiency can occur in both infant and adult patients receiving long-term 
PN. Taurine is necessary to solubilise bile salts and therefore for adequate biliary 
secretion and ileal reabsorption.(47) 
2.3.1.7.3  IV lipid emulsions  
Chronic cholestasis and severe IFALD are strongly associated with IV fat intake of 
>1g/kg/day, however this does not seem to be related to overfeeding per se. (47,48) 
The composition of lipid emulsions also plays a role. MCTs are oxidised faster in the 
liver than LCTs and data suggest LCT-MCT mixtures are less likely to cause hepatic 
complications than LCTs alone.(47) 
 
The mechanism by which fish oil-based omega 3 fatty acids influence IFALD can be 
divided into direct and indirect mechanisms. The direct actions include improved bile 
flow, decreased steatosis and anti-inflammatory and immune modulatory effects. 
Omega 3 fatty acids attenuate the inflammatory response by causing a shift from the 
omega 6-derived pro-inflammatory eicosanoids to the anti-inflammatory ones derived 
from omega 3 fatty acids. Indirect mechanisms include decreased intake of 
phytosterols and protection against oxidative stress with the addition of Vitamin E to 
fish oil-based lipid emulsions.(49) 
 
The phytosterol content of IV fat emulsions could also contribute to the development 
of IFALD.(47) Phytosterols are structurally similar to cholesterol and derived from 
plant products in the diet. Only 5 to 10% of phytosterols are absorbed in the small 
bowel. Phytosterols play an important role in inhibiting the absorption of cholesterol 
from the gut. In PN, phytosterols are delivered into the circulation and therefore 
higher than normal levels might be present. Unlike cholesterol, phytosterols cannot 
be converted into bile acids and therefore the excretion is limited. Levels of 
phytosterols correlate with the degree of IFALD. Fish oil containing lipid emulsions 
have lower levels of phytosterols.(50) 
2.3.1.8  Carnitine 
Carnitine plays an important role in fat metabolism and primary carnitine deficiency 
has been associated with the development of steatosis. Carnitine supplementation 
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has been shown to help mobilise hepatic fat stores and prevent steatosis in 
neonates.(47) 
2.3.1.9  Choline 
Choline is found in many food items but is not considered an essential nutrient. It is 
not a component of parenteral nutrition formulations because of the assumed 
endogenous synthesis from methionine. The conversion of methionine to choline 
might however be less effective when given parenterally than when it enters the liver 
via the portal vein.(47) Steatosis has been shown to resolve with choline 
supplementation in studies, but it is not commercially available.(27,47)  
2.3.1.10  Cyclic infusion 
Cyclic infusion of PN refers to the infusion of PN over a period of <24hours 
(generally 8–12 hours), thus allowing a rest period from PN.(47) Continuous infusion 
of PN could result in hyperinsulinemia and fat deposition in the liver.(47) 
 
Cyclic PN has been shown to lead to reduced serum liver enzyme concentrations 
and conjugated bilirubin concentrations, when compared to continuous infusion.(47) 
2.3.2  Prevention and treatment of intestinal failure associated liver disease 
2.3.2.1  Confirm the diagnosis 
Drug-induced hepatotoxicity is a possible complication of nearly all drugs 
metabolised by the liver. Therefore careful re-evaluation of patients’ drug charts 
should be done to rule out known hepatotoxic medications and/or herbal 
supplements.(47) 
 
Sepsis is common in patients receiving PN support and is often related to central 
venous access devices. Infections should be treated and measures should be taken 
to prevent recurrence. If small bowel bacterial overgrowth is suspected, the patient 
should be treated with appropriate antibiotics.(47) 
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2.3.2.2  Optimise oral and enteral nutrition 
Oral or enteral nutrition improves gut atrophy and preserves the immunologic 
integrity of the gut, thereby decreasing bacterial translocation and production of 
cytokines and endotoxins. Enteral or oral nutrition also improves gut motility and 
reduces intestinal stasis. Enteral or oral intake stimulates CCK secretion, which 
improves gallbladder contractility and reduces cholestasis and risk of sludge or 
gallstone formation.(27,47)  
2.3.2.3  Optimise parenteral nutrition 
The macronutrient content of the PN formulations should be reviewed and 
overfeeding avoided at all costs.(47) Careful consideration should be given to IV lipid 
emulsion administration, which should be limited to 1g/kg/min and be administered in 
the form of fish oil-containing lipid emulsions.(27,47) All sources of carbohydrate 
delivery should be considered and restricted to less than 5mg/kg/min.(27) 
Carbohydrates and lipids should be provided in a ratio of 70:30 of non-protein energy 
(NPE).(27) Cyclic PN should be considered to allow for a rest period from PN.(27,47) 
2.3.2.4  Pharmacological therapy 
Ursodeoxycholic acid is a hydrophilic bile acid that prohibits the absorption of bile 
salts in the ileum. A dose of 15–30mg/kg/day in long-term PN patients has shown a 
benefit in terms of lower serum liver enzymes but the long-term benefits are still 
unknown.(27,47) 
 
Metronidazole might be beneficial in patients with SBS by preventing small bowel 
bacterial overgrowth and deconjugation of bile acids.(27,47) 
2.3.2.5  Surgical therapy 
2.3.2.5.1  Prophylactic cholecystectomy 
Complications associated with cholelithiasis have a higher prevalence amongst 
patients requiring long-term PN support than among the rest of the population. 
Prophylactic cholecystectomy is therefore recommended in these patients when 
laparotomy is being done for other reasons.(27) 
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2.3.2.5.2  Bianchi procedure and serial transverse enteroplasty  
Both of these surgical techniques have been reported to improve function in patients 
with intestinal insufficiency.(27) The Bianchi procedure is a procedure where the 
bowel is divided longitudinally and each half is made into a tube.(20,27) The two tubes 
are then anastomosed in an end-to-end fashion, the result being doubling of the 
overall length and absorption surface.(20,27) 
 
During a serial transverse enteroplasty (STEP) procedure the bowel is stapled at 
regular intervals so that it takes a zigzag configuration. This increases transit time 
resulting in better absorption.(27) 
 
Both of these procedures are associated with 81–89% survival, 47–54% weaning off 
PN and 82–85% overall improvement in intestinal function.(27)  
2.3.2.5.3  Intestinal transplant 
Indications for intestinal transplantation include loss of venous access, recurrent life-
threatening central line-associated bloodstream infections and the development of 
IFALD.(51) Intestinal transplants are considered the only definitive treatment for 
patients with SBS who failed intestinal rehabilitation.(27) Patients with a bowel 
remnant of less than 50cm and without a colon should be referred to transplant 
centres as soon as possible as they will most likely be PN dependent.(27) 
 
When patients are considered for small bowel transplants they should undergo a 
liver biopsy and if fibrosis or cirrhosis is present, they should be considered for a 
simultaneous liver and small bowel transplant.(27) Intestinal transplantation should 
only be done in specialised centres able to provide maximal and appropriate medical 
and surgical therapies.(51) One-year survival for isolated intestinal transplant patients 
at expert centres is 86–93%.(51) 
2.4 Fistuloclysis 
Enteral nutrition has considerable advantages over PN support, including improved 
gut barrier function, reduction in infectious morbidity and improved immune function. 
Reconstructive surgery to restore intestinal continuity is difficult in patients where 
part of the small intestine has been deprived of enteral nutrition for months in part 
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due to marked atrophy of the intestine. This leads to inequality in the opposing bowel 
ends and poor quality of tissue for anastomosis.(4) 
 
Fistuloclysis, enteral feeding via an intestinal fistula, is an effective means of 
nutritional support.(35,52) Suitable patients for this approach of nutrition support 
include those with a distal fistula opening that can be intubated with a balloon 
retained gastrostomy tube; with no evidence of distal intestinal obstruction; and at 
least 75cm of small bowel distal to the fistula.(2,44) 
 
In a series of 12 patients described by Teubner et al., fistuloclysis replaced PN in 11 
out of 12 patients by increasing body weight and serum albumin, and decreasing 
hospital length of stay. There were no complications associated with fistuloclysis and 
the method was much more cost effective. Nutritional status was maintained for a 
median of 155 (range 19–422) days until definitive reconstructive surgery could be 
undertaken in 9 out of the 11 patients. Two patients who did not undergo surgery 
were maintained on fistuloclysis for nine months. One patient died at home as a 
result of ischemic heart disease, while the other one did not go for reconstructive 
surgery due to medical co-morbidity.(4) 
In a study by Wu et al. published in 2014, the researchers found that fistuloclysis 
could successfully improve liver function and nutritional status in patients with high-
output enteric fistulae. In this study 95 patients met the entry criteria and were 
enrolled in the study. They were divided into a control group who received enteral 
nutrition only and a fistuloclysis group who received enteral nutrition and fistuloclysis. 
The fistuloclysis group were further divided into three groups with regard to the 
location of the fistula, namely group 1: patients with jejunoileal fistulae; group 2: 
patients with biliary fistulae; and group 3: patients with duodenal fistulae. Enteral 
nutrition was administered via the distal fistula or nasojejunally in the case of biliary 
fistulae. The feeding goal was at least 30kCal/kg/day and 1,5–2g/kg protein/day with 
an additional 2g of nitrogen for every litre of fistula output. Both groups showed a 
statistically significant decline in hepatic indexes from baseline to 28 days. Both 
groups showed an increasing trend in nutritional parameters with the fistuloclysis 
group showing a statistically significant increase in albumin levels. The fistuloclysis 
group also showed a significant reduction in fistula output. With regard to the 
differences between the groups receiving fistuloclysis the biggest improvement in 
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total, direct and indirect bilirubin and ALP were seen in group 2, i.e. patients with 
biliary fistulae. The greatest improvement in albumin and total protein was also seen 
in patients in group 2. Patients in Group 1, i.e. patients with jejunoileal fistulae, 
showed the least improvement in these parameters. In terms of one-year survival, 
one patient (2,9%) in the fistuloclysis group died, while 10 patients (16,7%) in the 
control group were deceased at one-year follow-up.(6) 
 
A study by Coetzee et al published in 2014 describes the successful implementation 
of refeeding enteroclysis in a South African patient cohort managed in a tertiary 
hospital with a dedicated intestinal failure unit. This study included 20 patients with 
proximal enteric fistulae. In this publication patients were weaned of PN in a median 
of 20 days of admission to the unit and patients were maintained on fistuloclysis for a 
mean of 41 +/- 16 days. The mean output recorded in this study was 1940 +/- 606ml 
with a mean of 1360 +/- 460ml refed via the distal limb. Patients did not require 
supplementary intravenous fluid after the establishment of successful fistuloclysis. 
When additional fluids or electrolytes were required patients received oral 
rehydration solution. Twelve patients required additional enteral nutrition with a semi-
elemental tube feeds to achieve nutritional goals. Data was not recorded on minor 
complications such as skin excoriation, leaking of stoma appliances and blockage or 
feeding catheters.(5) 
 
In the Teubner et al. study, the protocol suggests starting with a polymeric feed via 
fistuloclysis, if a patient develops abdominal pain that lasts for >24 hours after the 
initiation of enteral feed or the patient has persistent diarrhoea, the enteral feed was 
changed to a semi-elemental formula. If the problem persisted with semi-elemental 
formulae, the patient would be changed to elemental enteral feeds. In the Levy et al. 
study, successful fistuloclysis was achieved with elemental formulae. A recent case 
study published by Wright et al. reported feeding a patient successfully by means of 
fistuloclysis using a 1,5kCal/ml polymeric enteral formula.(53) 
 
Benefits seen in patients receiving fistuloclysis might have been due to improvement 
in liver function and nutritional status along with a reduction in fistula output. Using 
this method of nutrition support has several advantages. Fistuloclysis is more 
effective in improving liver function than enteral nutrition alone. This may in part be 
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attributable to CCK, which is produced by the endocrine cells in the duodenum and 
upper jejunum, and stimulates gallbladder contractility and bile secretion. CCK is 
excreted in response to fats, proteins and amino-acids in the duodenum. Trypsin-
sensitive monitor peptide in the upper intestinal lumen is another potent CCK-
releasing factor, but might be lost through the fistula output. Therefore, continuation 
of the digestive system through fistuloclysis might improve CCK secretion and 
improve cholestasis.(6) 
 
Fistuloclysis of the enteric effluent provides enzymes, including salivary amylase, 
gastric pepsin and pancreatic enzymes, as well as bile acids necessary for optimal 
enteral nutrition utilisation. The fistula effluent also has the perfect pH to activate 
proenzymes and appropriate enzyme components for optimal enteral nutrition 
absorption.(6) 
 
In the intact gut, bile acids secreted in the duodenum are absorbed in the terminal 
ileum and recycled to the liver. In the patient with a fistula, this cycle is interrupted, 
leading to a lack of bile acids and subsequent malabsorption of fatty acids, 
phospholipids and fat-soluble vitamins. With fistuloclysis, the enterohepatic 
circulation of bile acids can be restored with improvement in nutritional status.(6) 
 
Fistuloclysis has the ability to decrease fistula output. High output from enteric 
fistulae is associated with high fluid and electrolyte loss, resulting in hyponatremia, 
hypochloremia, hypokalemia, metabolic acidosis/alkalosis and renal dysfunction. 
Fistuloclysis has an inhibitory effect on upper gastrointestinal secretions. It is 
speculated that this might be attributable to restoration of bowel continuity and 
physiological digestive processes.(6) 
 
Fistuloclysis may have several problems associated with the process, including tube-
dislodgement and skin corrosion from effluent leaking onto the skin. A rare 
complication is a ‘swallowed’ feeding tube, where the feeding tube is ingested into 
the intestine by peristalsis.(6)  
 
The development of IF is the consequence of diverse etiologies and 
pathophysiological consequences. The management of IF is a time-consuming 
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process, which entails long periods of hospitalisation and has profound cost 
implications. Optimisation of nutritional and medical status is the key goal in the 
management of these patients, while complications are kept to a minimum to prevent 
secondary insults. Fistuloclysis is a novel treatment that has been shown in the 
literature to be effective in maintaining and improving patients’ nutritional status to 
the point where they can undergo definitive surgery. In a resource-scarce 
environment we need to explore treatment options that are effective in promoting the 
medical and nutritional status of the patient, while minimising risk to the patient, 
improving quality of life and reducing cost. Fistuloclysis could be a feasible option for 
the management of IF in the South African context. The motivation for this study was 
to present the data from a tertiary institution and to gather information regarding the 
management of IF in other institutions as well as presenting a purposefully selected 
case study to describe the procedure and management of a patient receiving 
fistuloclysis. Figure 2.1 provides a conceptual framework illustrating the link between 
these diverse objectives and how it addresses the research question. This 
information will be valuable in terms of establishing equipment and training needs 
and the readiness of institutions to adapt to a novel nutritional management solution.  
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Figure 2.1 Conceptual framework for study objectives 
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CHAPTER 3:  METHODOLOGY 
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3.1 Research question 
How practical and acceptable is fistuloclysis in adult intestinal failure (IF) patients in 
the South African setting? 
3.2 Research aim 
To investigate the management of adult IF patients in tertiary hospitals in South 
Africa and determine how practical and acceptable fistuloclysis is. 
3.3 Study objectives 
1. To describe the implementation and management of the IF patient population in 
Groote Schuur Hospital, where fistuloclysis has been implemented successfully. 
2. To present one purposefully selected patient case study. 
3. To investigate the current management of type 2 and type 3 IF patients in the 
tertiary hospitals in South Africa, as well as, the perceptions and opinions 
regarding fistuloclysis as a management option for this patient population amongst 
doctors, stoma sisters and dietitians involved in their care. 
 
The methodology for each objective will be discussed separately. 
3.4 Objective 1 
3.4.1  Study population 
Adult patients admitted to Groote Schuur Hospital IF unit between January 2009 and 
May 2014 were assessed for eligibility, based on set inclusion and exclusion criteria, 
for inclusion in the study sample.  
 
Inclusion criteria 
• Patients older than 18 years of age 
• Established type 2 and type 3 IF 
• Able to establish fistuloclysis successfully 
• Admitted to Groote Schuur Hospital intestinal failure unit between 1 January 2009 
and discharged by 31 May 2014.  
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Exclusion criteria 
• Patients younger than 18 years of age 
• Unable to establish fistuloclysis successfully 
• Patients admitted to and treated in Groote Schuur Hospital IF unit before 1 
January 2009 or still in the unit after 31 May 2014. 
3.4.2  Study design 
The study design was a retrospective record review of the medical data collected 
from the patient folders.  
3.4.3  Study methods 
Data was collected retrospectively from patient folders and entered into an Excel 
spread sheet. All information was collected under patient folder numbers and no 
personal details were associated with the collected data. Information was collected 
on demographics, surgical interventions, gastrointestinal anatomy, nutritional 
management, biochemical markers and intake and output. See Addendum A for the 
data capture sheet.  
 
The Groote Schuur database for IF patients was used to recruit patients for the 
study. The database captured information on patients admitted to the IF unit 
between January 2009 and October 2013. Additional patient records were searched 
for patients admitted between 1 November 2013 and 31 May 2014 to determine 
additional patients who fitted the inclusion criteria. Fifty-nine patients were identified 
who were admitted and completed treatment between 1 January 2009 and 31 May 
2014. Of those, 22 patients fitted the inclusion criteria. One patient was excluded due 
to their age being younger than 18 years. Another patient was excluded due to the 
fact that he withdrew from the treatment option, fistuloclysis, for personal reasons. 
The medical data of a further three patients were unobtainable and they were 
therefore excluded from the final study sample. Seventeen patients were included in 
the final data analysis. (Figure 3.1) 



















Figure 3.1: Screening process of selecting patients for inclusion  
3.4.4  Data management and statistical analysis 
• Descriptive statistics were used to report data on patient demographics and 
characteristics.  
• Where patients had more than one episode of fistuloclysis during their admission 
data were collected and included in the analysis from the longest period of 
fistuloclysis.  
• Patients were regarded as having proximal IF when the length of small bowel from 
the duodenal-jejunal (DJ) flexure to the first defect or stoma were less than 
150cm. Where anatomical terms were given in the medical notes, instead of 
measurements, mid small bowel or duodenum or jejunum were regarded as 
proximal small bowel.  
• Length of stay in the IF unit was expressed as a median for the patient population.  
• Total number of days on parenteral nutrition (PN) in the unit was collected for each 
patient and expressed as a median for the patient population.  
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• Number of days that PN was continued for after commencement of fistuloclysis 
was collected and expressed as a median for the patient population. 
• The number of days patients were managed on fistuloclysis was collected for each 
patient and expressed as a median for the patient population.  
• Days spend at home on fistuloclysis, if it was applicable, were calculated and 
expressed as a median for the applicable patients.  
• The average fistula/stoma output was calculated for three time periods: 
• Period from admission until discharge from the unit. 
• Period form admission until definitive surgery was performed. 
• Period of fistuloclysis. 
The median of all of these were calculated and expressed as a median for the 
patient population. 
• Average fistula/stoma output re-infused daily via fistuloclysis was calculated and 
expressed as a percentage of the output. 
• Days until definitive surgery were collected and expressed as a median for the 
patient population.  
• Days from definitive surgery until discharge from hospital were calculated and 
expressed as a median for the patient population.  
• Body weight was recorded at weekly intervals for the duration of the fistuloclysis 
period when a measurement was available. The total change in body weight for 
the period of fistuloclysis was calculated. The rate of weight change was 
calculated per week. The median values for both weight change and rate of 
weight change were calculated for the study population.  
• The number and type of fistuloclysis catheter-related complications were recorded 
per patient if it was available in the patient record. The total number of 
complications for the study population was calculated and expressed as a number 
per 50 catheter days.  
• PN bloods, which include electrolytes, urea, creatinine, calcium, magnesium, 
phosphate, liver function tests, albumin and a full blood count, is done routine on a 
Monday and Tuesday in the unit. Biochemistry was recorded on day one, day 14 
and day 28 of fistuloclysis, or as close as possible according to the availability of 
biochemical data. Due to the skewness of the data and the small data set non-
parametric statistical analysis were applied. The median for each of the 
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biochemical measurements at each time point was calculated as well as the 
minimum and maximum value. The Wilcoxon signed rank test were applied to test 
for significance with a p<0.05 regarded as significant.  
• Patient outcome was reported as discharged alive from hospital or deceased 
during hospital stay as well as whether the patient regained nutritional autonomy. 
3.5 Objective 2 
3.5.1  Study population 
One patient was purposefully selected from the patient population in objective 1 to 
present as a case study. 
3.5.1.1  Inclusion criteria 
Meeting the inclusion criteria under objective 1. 
3.5.2  Study design 
The case study was presented as a retrospective patient discussion.  
3.5.3  Study methods 
One patient was purposefully selected and a case study presented in the form of a 
journal article. No patient name or personal identifiers apart from age and sex were 
used in writing up the case report. The case study was submitted, peer-reviewed and 
accepted for publication by the South African Journal of Clinical Nutrition (SAJCN). 
The case study appeared in South African Journal of Clinical Nutrition 
2014;27(4):230-236.  
3.5.4  Statistical analysis 
Data was reported as a descriptive retrospective case study. 
3.6 Objective 3 
3.6.1  Study population 
Medical doctors, stoma therapists and dietitians working in South Africa who are 
involved in the management of patients with type 2 and type 3 IF. 
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3.6.1.1  Inclusion criteria 
• Medical doctors currently working in a South African hospital involved in the 
management of type 2 and type 3 IF patients.  
• Stoma therapists currently working in a South African hospital involved in the 
management of type 2 and type 3 IF patients.  
• Dietitians currently working in a South African hospital involved in the 
management of type 2 and type 3 IF patients.  
3.6.1.2  Exclusion criteria 
• Medical doctors, stoma therapists and dietitians not currently working in a South 
African hospital and not involved in the management of type 2 and type 3 IF 
patients. 
• Medical doctors, stoma therapists and dietitians currently working in Groote 
Schuur Hospital. 
3.6.2  Study design 
A descriptive observational study of the current management of type 2 and type 3 IF 
patients in South African hospitals as well as of the perceptions and opinions of 
doctors, stoma therapists and dietitians working in South African hospitals about 
fistuloclysis as a treatment option for IF was done.  
3.6.3  Study methods 
3.6.3.1  General procedure 
The date regarding current management of type 2 and type 3 IF patients as well as 
the perceptions and opinions regarding fistuloclysis as a treatment option amongst 
medical doctors, stoma therapists and dietitians working in South African hospitals 
were obtained by means of questionnaires. A separate questionnaire was compiled 
for each occupational group.  
3.6.3.2  Questionnaire development  
Separate questionnaires were developed for every occupation group through 
consultation with professionals currently involved in the management of IF patients in 
Groote Schuur Hospital, where fistuloclysis has been implemented successfully. 
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Content validity was ensured through consultation with the various occupation 
groups. Stoma therapists evaluated the content included in the questionnaire for 
stoma therapists while the doctor and dietetic questionnaires were evaluated for 
content by a surgeon working in the area and who is involved in the day-to-day 
management of intestinal failure patients. After completion of the questionnaire 
development the same group of people had the opportunity to complete the 
questionnaires to ensure face validity.   
The questionnaires were managed through the web-based system, Survey Monkey. 
The first page of the survey included a detailed letter giving participants background 
to the study and the investigators. In an attempt to adhere to the inclusion and 
exclusion criteria as stipulated above questions were build into the questionnaires 
that would exit participants from the survey early on if they did not fit the given 
criteria. If a participant fitted all the inclusion criteria but were unfamiliar with the term 
“fistuloclysis” they were given a brief explanation and allowed to continue with the 
survey. All questions required an answer before a participant could move on to the 
next question. If a participant responded negatively to a question that had questions 
following onto it the questionnaire skipped to the next unrelated question 
automatically. (Addendum B, C, D) 
3.6.3.3  Selection of participants 
An electronic mail (e-mail) was sent out via the Association for dietetics in South 
Africa (ADSA) and the South African Society for Parenteral and Enteral Nutrition 
(SASPEN) mailing lists to recruit dietitians for participation.  
An e-mail was sent out via the South African Stomatherapy Association (SASA) to 
recruit stoma therapists to participate in the study.  
A second e-mail was sent out two weeks after the first to both groups.  
Each survey remained open for completion for a period of four weeks.  
Surgeons were recruited for participation by sending an e-mail to one representative 
at each of the following seven academic centres in South Africa that teach medicine, 
excluding the University of Cape Town (UCT), due to the fact that UCT is affiliated 
with Groote Schuur Hospital.  
• University of Pretoria 
• University of Witwatersrand 
• University of the Free State 
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• Sefako Makgatho Health Sciences University (SMU) (Previously MEDUNSA) 
• University of Stellenbosch 
• University of Kwazulu-Natal 
• Walter Sisulu University (Previously University of the Transkei) 
 
The e-mail contained a link to the relevant Survey Monkey questionnaire. 
3.6.4  Statistical analysis 
The data obtained from Survey Monkey were downloaded in the form of an Excel 
spread sheet. The data were analysed by the principle investigator and reported as 
descriptive statistics.  
3.7 Ethics 
Ethics approval was obtained from the Stellenbosch University Health Research 
Ethics Committee under ethics reference number S14/09/177.  
 
Due to the retrospective nature of the data collected under objectives 1 and 2 and 
the anonymity of the data collected the researchers requested a waiver of the 
informed consent process. For objective 3 questionnaires contained a detailed 
information sheet explaining the study and the investigators involved. Completion of 
the questionnaires was done anonymously through Survey Monkey and willingness 
to participate in the study was regarded as informed consent. 
 
The study was conducted in accordance with the Declaration of Helsinki.   
3.7.1  Protocol deviations 
3.7.1.1  Objective 3 
As per the original protocol surveys were to be sent to a doctor, stoma therapist and 
dietitian for completion at each of the 13 academic hospitals identified in South 
Africa. Due to difficulties and time constraints in obtaining permission from the 
National Department of Health to conduct this research in the identified public 
hospitals the researchers were forced to deviate from the protocol. Surveys were 
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sent via societies representing the different occupation groups and through 
Universities teaching medicine, as explained in the methodology.  
Due to the more generalised study population the surveys were conducted over four 
weeks instead of two as stipulated in the initial protocol to allow for more time to 
obtain responses.  
3.7.1.2  Ethics 
Ethics approval from The University of Cape Town Human Research Ethics 
Committee was waived, by the committee themselves, due to the fact that approval 
was already obtained from another recognised ethical authority. Institutional approval 
was obtained from Groote Schuur Hospital for collection of data from patient folders. 












































4.1 Objective 1 
To describe the implementation of fistuloclysis and the management of the 
intestinal failure patient population in Groote Schuur Hospital, where fistuloclysis 
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The use of fistuloclysis in an intestinal failure population in a South 
African tertiary hospital 
Du Toit Aa,b, Boutall ABTc, Blaauw Ra 
a
: Division of Human Nutrition, Faculty of Medicine and Health Sciences, Stellenbosch University 
b
:Department of Dietetics, Groote Schuur Hospital, Cape Town 
c
: Department of Surgery, Groote Schuur Hospital, Cape Town 
Introduction 
Intestinal failure (IF) is a complex pathophysiological condition with a diverse 
aetiology. IF and its complications are associated with significant cost, a large 
component of which is parenteral nutrition (PN). Owing to the nature and complexity 
of IF, it often requires long-term hospitalisation and PN support to improve or 
maintain nutritional status, while allowing for enough time between surgeries for 
peritoneal adhesions to mature and complications to be treated.(1,2) Internationally, 
and at Groote Schuur Hospital, specialised units adhere to a waiting time before 
carrying out definitive surgery ranging between six weeks and six months.(1,2) In a 
recent cost analysis done by the National Department of Health, PN was found to be 
one of the top ten pharmacy expenditures, contributing a major cost to patient 
treatment.(3) Groote Schuur Hospital started a unit specialising in managing IF 
patients in 2009 and currently has a six-bed cubicle within the colorectal surgery 
ward where these patients are managed. Fistuloclysis, i.e. enteral feeding via an 
intestinal fistula, has been successfully implemented within this unit as a means of 
nutritional support and in doing so it has been possible to wean patients off PN and 
eliminate the cost and side effects associated with it.(4,5) In a series of 12 patients 
described by Teubner et al., fistuloclysis replaced PN in 11 out of 12 patients by 
increasing body weight and serum albumin, and decreasing hospital length of stay.(6) 
There were no complications associated with fistuloclysis and the method was more 
cost effective.(6) In a study by Wu et al. published in 2014, the authors found that 
fistuloclysis could successfully improve liver function and nutritional status in patients 
with high-output enteric fistulae.(7) 
 
Doctors, nursing staff, stoma therapists and dietitians involved in this unit are familiar 
with and experienced in the field of IF and fistuloclysis. Fistuloclysis is an effective 
and feasible way of managing these patients and often the only alternative to PN 
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support. Although an internationally recognised practice, to the researcher’s 
knowledge this is an underutilised method of nutritional support within the South 
African context. The purpose of this study was therefore to describe the Groote 




Adult patients admitted to Groote Schuur Hospital IF Unit between January 2009 and 
May 2014 were eligible for inclusion in the study, provided they met the following 
inclusion criteria.  
Inclusion criteria 
• Older than 18 years of age 
• Diagnosed with established type 2 or type 3 IF 
• Fistuloclysis able to be implemented successfully 
• Admitted to Groote Schuur Hospital IF unit on or after 1 January 2009 and 
discharged by 31 May 2014 
Study methods and statistical analysis 
The study design was a retrospective record review of the medical data collected 
from the patient folders.  
Where patients had more than one episode of fistuloclysis during their admission, 
data were collected and included in the analysis from the longest period of 
fistuloclysis. Patients were regarded as having proximal IF if the length of small 
bowel from the duodenal-jejunal (DJ) flexure to the first defect or stoma were equal 
to or less than 150cm. Where anatomical terms were given in the medical notes, 
instead of measurements, mid small bowel, duodenum or jejunum were regarded as 
proximal small bowel.  
 
Information was collected on demographics, surgical interventions, gastrointestinal 
anatomy, nutritional management, biochemical makers, and intake and output. 
Fifty-nine patients were identified that fitted the time period for admission and 
completion of treatment between 1 January 2009 and 31 May 2014. Twenty-two 
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patients out of the 59 were treated by means of fistuloclysis. One patient was 
excluded owing to age younger than 18 years. Another patient was excluded 
because he withdrew from the treatment option, namely fistuloclysis, for personal 
reasons. The medical data of a further three patients were unobtainable and they 
were therefore excluded from the final study sample. Seventeen patients were 
included in the final data analysis (Figure 1). 
 
 
Figure 1: Study population selection process 
 
Owing to the skewness of the data and the small data set non-parametric statistical 
analysis was applied. Descriptive statistics were used to report data on patient 
demographics and characteristics. 
The length of stay, number of days on PN, and number of days on fistuloclysis in the 
IF unit were calculated and expressed as a median for the patient population.  
The number of days that PN was continued after commencement of fistuloclysis was 
collected and expressed as a median for the patient population. The number of days 
59 Patients fitting 
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21 Patients treated by 
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17 Patients 
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1 patient <18years 
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3 patients medical 
records unobtainable 
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spent at home on fistuloclysis, if applicable, was calculated and expressed as a 
median.  
The average fistula/stoma output was calculated for three time periods: 
• Period from admission until discharge from the unit 
• Period from admission until definitive surgery was performed 
• Period of fistuloclysis 
The median of all of these was calculated and expressed as a median for the patient 
population. 
Median fistula/stoma output re-infused daily via fistuloclysis was calculated and 
expressed as a percentage of the output.  
The days until definitive surgery and days from definitive surgery until discharge 
were collected and expressed as a median for the patient population.  
Body weight was recorded at weekly intervals for the duration of the fistuloclysis 
period if the measurement was available. The total change in body weight for the 
period of fistuloclysis was calculated. The rate of weight change was calculated per 
week. The median values for both weight change and rate of weight change were 
calculated for the study population.  
The number and type of fistuloclysis catheter-related complications were recorded 
per patient if it was available in the patient record. The total number of occurrences 
of complications for the study population was calculated and expressed as a number 
per 50 catheter days. The types of catheter-related complications were reported as 
descriptive statistics.  
PN bloods, which included electrolytes, urea, creatinine, calcium, magnesium, 
phosphate, liver function test (LFTs), albumin and a full blood count, was done 
routinely on a Monday and Thursday in the unit. Biochemistry was recorded on day 
one, day 14 and day 28 of fistuloclysis, or as close as possible to these days, 
according to the availability of biochemical data. The median for each of the 
biochemical measurements at each time point was calculated, as well as the 
minimum and maximum values. The Wilcoxon signed rank test was applied to test 
for significance with a p<0.05, regarded as significant.  
Patient outcome was reported as: discharged alive from hospital or deceased during 
hospital stay as well as whether the patient regained nutritional autonomy. 
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Results 
Seventeen patients were included in the study (Figure 1). Patient demographics and 
characteristics are displayed in Table 1. The majority of patients were male 
(n=13/17, 76,5%) and the median age was 42 years. The most common aetiology of 
IF was trauma-related (n=5/17, 29,4%). Complications secondary to appendicitis 
(n=2/17, 11,8%), small bowel obstruction (n=3/17, 17,6%) and iatrogenic bowel 
injury (n=2/17, 11,8%) also ranked high among causative factors. The majority of 
patients presented with proximal intestinal failure (n=13/17, 76,5%), defined as the 
first defect being within 150cm from the DJ flexure. A total of 47% of patients 
(n=8/17) had an open abdomen. The median time spent in the IF unit was 93 days 
with a wide range of 31 days to 319 days. During this period patients spent a median 
of 19 days on PN and 52 days on fistuloclysis (Table 2). PN was continued for a 
median of two days after the start of fistuloclysis. Only one of the 17 patients 
(n=1/17, 6%) could not be weaned off PN with this approach.  
Table 1: Demographics and characteristics of patients (n=17) 
 N % 
Gender Female 4 23,5% 
Male 13 76,5% 
Age (years) 42 (24–72)   
Length of stay in unit (days) 93 (31–319)   
Aetiology Trauma 5 29,4% 
Appendicitis 2 11,8% 
Small bowel obstruction 3 17,6% 
Iatrogenic injury 2 11,8% 
Abdominal tuberculosis 1 5,9% 
Bowel perforation 1 5,9% 
Mesenteric ischemia 1 5,9% 
Radiation enteritis 1 5,9% 
Anastomotic leak 1 5,9% 
Proximal intestinal failure No 4 23,5% 
Yes 13 76,5% 
Open abdomen No 9 52,9% 
Yes 8 47,1% 
Total PN days in IF unit 19 (0–258)   
Days PN after starting fistuloclysis 2 (0–63)   
Able to wean of PN with fistuloclysis? No 1 5,9% 
Yes 16 94,1% 
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Receiving additional feed via fistuloclysis? No 14 82,4% 
Yes 3 17,6% 
Table 2: Data on output and fistuloclysis 
 
N Median Minimum Maximum 
Total days on fistuloclysis 17 52 10 128 
Days spend at home on fistuloclysis 4 32,5 22 42 
Median output for total admission period (ml) 17 1 279 779 3 712 
Median output for period from admission until 
definitive surgery (ml) 
17 1 674 969 4 002 
Median output for period of fistuloclysis (ml) 17 1 478 900 4 398 
Median re-fed for period of fistuloclysis (ml) 17 980 341 1 812 
% Effluent re-infused 17 71,26% 17,57% 88,00% 
 
Patients had a median output of 1 674ml per day for the period from admission until 
definitive surgery, with a range of 969ml–4 002ml. During the period of fistuloclysis 
the median output was 1 478ml, ranging between 900ml–4 398ml. Patients received 
a median of 980ml (71%) of effluent back via fistuloclysis during this period (Table 
2). Most patients received only the effluent via fistuloclysis (n=14/17, 82,4%), 
however three (n=3/17, 17,6%) patients received additional semi-elemental feeds via 
fistuloclysis. Four patients were able to go home for a median period of 32,5 days on 
fistuloclysis.  
 
Complications related to fistuloclysis were reported a total of 80 times (Table 3). 
Complications that were most prevalent were bags leaking (n=30/80, 37,5%), 
fistuloclysis catheters getting blocked (n=20/80, 25%), and catheters becoming 
dislodged (n=17/80, 21,25%). This equated to a median of 3,51 complications per 50 
fistuloclysis catheter days. 
Table 3: Fistuloclysis related complications 
Complications Number (n=80) Percentage  
Leaking stoma bags 30 37,5% 
Blocked fistuloclysis catheters 20 25% 
Dislodged catheters 17 21,25% 
Skin erosion 1 1,25% 
Effluent discarded incorrectly 1 1,25% 
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Clostridium Difficile 1 1,25% 
Patient refusing intermittently 5 7,5% 
Developed fistula in distal limb 1 1,25% 
Obstruction in distal limb 1 1,25% 
Stoma prolapse 1 1,25% 
Abdominal cramping 1 1,25% 
 
Biochemistry results collected at the three time-intervals are presented in Table 4.  
Both total bilirubin and conjugated bilirubin medians were within normal range 
throughout, although some outliers were found. Total bilirubin improved from a 
median of 8,5 μmol/L to 6,0 μmol/L between day 0 and day 28, the range also 
improved from 3–30 μmol/L to 2–12 μmol/L. Conjugated bilirubin improved slightly 
from 4 μmol/L on day 0 to 3,5 μmol/L on day 14 and then stayed stable at that level. 
The range also improved from 1–15 μmol/L to 1-7 μmol/L (Figure 2). 
 
Figure 2: Conjugated Bilirubin 






Median Minimum Maximum 
Sodium (mmol/L) Day 0 135-147 135 124 141 
 Day 14 135–147 134 127 144 
 Day 28 135–147 132 128 141 
Potassium (mmol/L) Day 0 3,3–5,3 4,2 3,2 6 
 Day 14 3,3–5,3 4,2 3,6 5,4 
 Day 28 3,3–5,3 4,1 2,6 4,7 
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Urea (mmol/L) Day 0 2,6–7 6,2 1,7 15,8 
 Day 14 2,6–7 6,7 2,1 11,9 
 Day 28 2,6–7 4,9 2,8 11,1 
Creatinine (μmol/L) Day 0 64–104 54 22 129 
 Day 14 64–104 63 23 183 
 Day 28 64–104 59 27 172 
Corrected Calcium (mmol/L) Day 0 2,05–2,56 2,33 1,95 2,85 
 Day 14 2,05–2,56 2,40 2,12 2,84 
 Day 28 2,05–2,56 2,41 1,83 2,74 
Magnesium (mmol/L) Day 0 0,65–1,1 0,66 0,42 1 
 Day 14 0,65–1,1 0,72 0,57 0,84 
 Day 28 0,65–1,1 0,70 0,34 0,93 
Phosphate (mmol/L) Day 0 0,8–1,4 1,21 0,44 1,65 
 Day 14 0,8–1,4 1,31 0,52 1,59 
 Day 28 0,8–1,4 1,15 0,31 1,91 
Total Bilirubin (μmol/L) Day 0 0–21 8,5 3 30 
 Day 14 0–21 7 3 13 
 Day 28 0–21 6 2 12 
Conjugated Bilirubin (μmol/L) Day 0 0–6 4 1 15 
 Day 14 0–6 3,5 1 8 
 Day 28 0–6 3,5 1 7 
Albumin (g/L) Day 0 35–52 27*
 
11 39 
 Day 14 35–52 30,5 17 46 
 Day 28 35–52 36* 16 45 
Alkaline Phosphatase (ALP) (U/L) Day 0 40–120 161 42 416 
 Day 14 40–120 144 56 344 
 Day 28 40–120 155,5 45 372 
Gamma-glutamyl Transpeptidase 
(GGT) (U/L) 
Day 0 0–60 163 45 406 
Day 14 0–60 99,5 47 500 
Day 28 0–60 125,5 36 592 
Alanine Aminotransferase (ALT) 
(U/L) 
Day 0 5–40 25 7 132 
Day 14 5–40 21,5 6 152 
Day 28 5–40 31,5 6 140 
Aspartate Aminotransferase (AST) 
(U/L) 
Day 0 5–40 31 8 60 
Day 14 5–40 20,5 13 71 
Day 28 5–40 20,5 12 68 
White cell count (x10
9
/L) Day 0 4–10 12,24 4,94 31,84 
 Day 14 4–10 10,97 5,24 23,77 
 Day 28 4–10 9,88 5,50 25,10 
* p=0.001 
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The liver function test results are displayed in Figure 3. Alkaline phosphatase (ALP) 
showed a decreasing trend between day 0 and day 14 and then stabilised (Figure 
4). Gamma-glutamyl transpeptidase (GGT) showed a sharp decrease between day 0 
and day 14 and then increased again slightly over the next 14 days (Figure 5). 
Alanine aminotransferase (ALT) decreased over the initial 14 days and then 
increased to a higher level at day 28, but the median remained within normal range 
throughout. Aspartate aminotransferase (AST) decreased sharply initially and then 
remained stable, the median remained within normal range throughout.  
 
There was a statistically significant increase in the median serum albumin level 
between day 0 and day 28 from 27 g/L to 35 g/L (p=0.001) (Figure 6). C-reactive 
protein (CRP) values were not available, but the median white cell count did improve 
to within normal range between day 0 and day 28, from 12,24x109/L to 9,88x109/L.  
 
Figure 3: Liver function tests 
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Figure 5: Gamma-glutamyl transpeptidase 
 
 
Figure 6: Albumin 
 
Data on body weight was only available for 13 patients (n=13/17). Body weight did 
not improve during the period of fistuloclysis, but showed a median decrease of 3kg 
for the period of fistuloclysis at a rate of 300g per week (Table 5). The individual 
patient body weight trends are displayed in Figure 7. 
 
Regarding outcome, patients waited a median time of 85 days before definitive 
surgery. Only 15 patients underwent definitive surgery. None of the patients whose 
folders were unobtainable died; therefore mortality for all patients managed with 
fistuloclysis was 10% (n=2/20). The only two deaths in the fistuloclysis group 
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occurred prior to definitive surgery. Mortality among the 37 patients who were not 
managed on fistuloclysis was 13,5% (n=5/37). Postoperative complications only 
occurred in three patients (n=3/15, 20%) and resolved with conservative 
management in two of these patients (n=2/3, 66%). The third patient had a negative 
relook laparotomy and subsequently settled. Patients were discharged a median of 
12 days post definitive surgery and all patients who underwent definitive surgery 
regained nutritional autonomy (Table 6). 
Table 5: Change in body weight (kg) 
 Weight difference Rate of weight change 
Median -3.0 -0.3 
Minimum -15.00 -2.00 
Maximum 5.00 0.45 
 
 
Figure 7: Individual patient weight trends 
Table 6: Patient outcome 
  N % 
Days until definitive surgery 85 (57–300)   
Complications post definitive surgery No 12 80% 
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Enterocutaneous fistula 2 13,3% 
Required relook 1 6,7% 
Total 15  


















Regained nutritional autonomy 
No 0 0% 
 
Yes 15 100% 
 
Total 15  
Days from definitive surgery until discharge 
12 (4–79)   
Discussion 
The concept of IF was first defined by Fleming and Remington in 1981 as “a 
reduction in the functional gut mass below the minimal amount necessary for 
adequate digestion and absorption of food”.(8–10) In 2015 the European Society for 
Clinical Nutrition and Metabolism (ESPEN) published recommendations on the 
definition and classification of IF in adults.(8) These recommendations include a 
definition of IF, a functional and pathophysiological classification for acute and 
chronic IF and a clinical classification of chronic IF. According to the ESPEN 
classification, IF can be defined as the reduction of gut function below the minimum 
necessary for absorption of macronutrients and/or water and electrolytes, such that 
intravenous (IV) supplementation is required to maintain health and/or growth.(8) 
Micronutrients were not included in the definition and micronutrient deficiencies 
alone due to gut impairment are not classified as IF.(8) IF has been sub-divided into 
three types based on the onset and expected metabolic impact and outcome.(8,11,12) 
Type 1 IF is usually self-limiting, short term and often perioperative.(13–15) Common 
causes of type 1 IF include mechanical intestinal obstruction and non-mechanical 
ileus.(14) Type 1 IF usually resolves within seven to 14 days with conservative 
management, nasogastric drainage and might require short-term PN support.(14,16) 
Type 2 IF is a serious condition associated with a higher incidence of mortality.(8,14) 
Patients usually develop type 2 IF as a result of complications of abdominal surgery 
leading to abdominal sepsis and intestinal fistulation.(14) An estimated 10% of 
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patients will also have significant reduction in intestinal length at the time of 
diagnosis.(14) Type 2 IF is usually not self-limiting, with the exception of patients with 
simple intestinal fistulation where spontaneous closure may occur with effective 
nutritional and medical support.(14) Type 3 IF refers to a chronic condition in a 
metabolically stable patient, requiring long-term PN support, often for years, with 
careful monitoring for complications.(8,13,15)   
 
According to patient records, a total of 59 patients were treated in the IF unit at 
Groote Schuur Hospital over a period of five years and four months. According to 
European data, the prevalence of IF is 18 per million people per year, based on 
people receiving parenteral nutrition for more than 14 days.(14) If this were 
extrapolated to the South African context, this would equate to roughly 970 cases of 
IF in South Africa per year. In the light of these statistics 59 cases over a period of 
five years and four months might seem minimal for a tertiary hospital with a 
dedicated IF unit. This number is however only representative of patients who 
developed complicated IF which progressed to type 2 and type 3 and required expert 
care in a dedicated unit. This number would not be representative of patients with 
uncomplicated IF. Furthermore one has to suspect that a large number of patients 
are being managed in non-dedicated units with unknown results.  
 
Only 17 patients, who fitted the inclusion criteria and were managed on fistuloclysis, 
were included in the study. It is important to note that one patient declined 
fistuloclysis as an approach to nutritional management. This patient had been 
transferred to the Groote Schuur Hospital IF Unit from a private hospital for further 
management with fistuloclysis. The patient refused fistuloclysis and preferred to be 
treated in a private treatment facility with conventional methods, which entailed PN to 
maintain nutritional status.  This observation is important since some patients might 
not find fistuloclysis acceptable.  
Trauma has been identified as the leading cause of IF, accounting for 29% of cases 
in this study. Other aetiologies included small bowel obstruction, iatrogenic injuries 
and post appendisectomy complications. Based on international data from the United 
Kingdom (UK) Crohn’s disease, intestinal ischemia and surgical complications were 
the major contributing causes for IF resulting in patients requiring long-term or home 
parenteral nutrition (HPN).(15) Data from other European countries and Canada show 
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similar results. The main aetiology for HPN in the United States of America (USA) 
and Japan is cancer, contributing 42% and 40% respectively.(15) This included 
malignant small bowel obstruction (SBO), short bowel syndrome (SBS) and high 
output fistulae due to malignancy.(15) When surgical complications in terms of 
iatrogenic injuries, anastomotic leaks and complicated appendisectomies were 
combined in the current study, this resulted in 29% of cases, making trauma and 
postsurgical complications the leading causes of IF in this patient cohort. It is evident 
that the population treated at Groote Schuur, and we could probably extend this to 
the greater South Africa, is based on a different causative factor, namely trauma.  
 
Patients were categorised as having proximal or distal IF based on the level of the 
most proximal stoma or fistula, the majority of patients in this group presented with 
proximal IF, 76,5%. The clinical manifestation of SBS is associated with less than 
200cm of small bowel remaining in continuity, even if the total length of the small 
bowel including the part that is bypassed or in discontinuity is of normal length.(8,17,18) 
Conditions leading to SBS most commonly affect the jejunoileal segment and less 
commonly the colon.(19) The pathophysiological manner in which SBS causes IF is 
due to extensive loss of absorptive surface area (8,18), while the pathophysiological 
manner in which fistulae cause IF is due to the enteric content being lost through a 
proximal opening or by bypassing a significant segment of gut in the case of internal 
enteroenteric fistulae.(8,20,21) This effectively leads to a situation of ‘short bowel 
syndrome’.(8,22) Based on these definitions, the presence of a stoma or fistula at the 
set level of 150cm would imply a patient being at risk of malnutrition on the basis of 
SBS and would have had to be treated accordingly. All SBS patients will require PN 
support in the immediate postoperative phase to maintain nutritional status.(19) Bowel 
adaptation usually occurs within the first two years following the last surgical 
intervention and patients would usually require PN or enteral nutrition support during 
this phase until sufficient adaptation has occurred.(23,18,19) By applying fistuloclysis, 
bowel length can be improved by employing the entire available bowel.  
 
Apart from the proximity of the first defect or stoma, a high-output fistula or stoma is 
commonly associated with PN. The physiological classification of fistulae is based on 
the output.(8,24,20,25) Less than 200ml effluent per day is considered low-output while 
200–500ml per day is classified as moderate output.(8,26,24,27,25) A fistula effluent of 
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more than 500ml per day in the fasted state is considered as a high-output fistula 
and is associated with a higher morbidity and mortality.(8,28,26,24,25) Edmunds et al., 
demonstrated a mortality rate of 54% in patients with high-output fistulae while 
patients with low-output fistulae had a mortality rate of 16%.(24) This was supported 
by Levy et al., who demonstrated a mortality rate of 50% and 26% respectively in 
patients with high- and low-output fistulae.(24) The median daily output for the period 
from admission until definitive surgery for the current group was 1 674ml, well above 
the 500ml that defines a high-output fistula. Patients with fistulae should be able to 
tolerate polymeric enteral formula, unless the patient has less than 120cm of bowel 
left, documented intolerance to polymeric feed or experience high fistula output.(25) In 
the case of fistuloclysis where there is distal bowel available the presence of a high-
output fistula becomes less threatening to the patient’s nutritional status, provided it 
can be implemented successfully. In the current study 94% of patients could be 
weaned off PN successfully by using fistuloclysis to recruit all or most of the 
available gut. This was possible with re-infusion of 71,25% of effluent. PN could be 
stopped a median of two days after initiation of fistuloclysis. Patients were 
maintained on fistuloclysis for a median of 52 days. In a series of 12 patients 
described by Teubner et al., fistuloclysis replaced PN successfully in 11 out of 12 
patients.(6) Nutritional status was maintained for a median of 155 (range 19–422) 
days until definitive reconstructive surgery could be undertaken.(6) 
 
According to the literature suitable patients for this approach of nutritional support 
include those with a distal fistula opening that can be intubated with a balloon-
retained gastrostomy tube, with no evidence of distal intestinal obstruction and with 
at least 75cm of small bowel distal to the fistula.(2,29) It should however be considered 
that the colon can also utilise maldigested carbohydrate and protein through 
anaerobic bacterial fermentation providing an additional source of nutrition.(11,12,18,30) 
Patients with colon continuity can salvage up to 1 000 additional calories per day 
from unabsorbed carbohydrates.(30)  
 
A total of eight patients had open abdomens which presents a high risk for the 
development of fistulae with an incidence of 5–19%.(25) An enteroatmospheric fistula 
(EAF) is a sub-set of fistulae that arise in the setting of an open abdomen with 
exposed viscera.(5,25,26,29) The longer the abdomen remains open with a temporary 
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dressing the higher the likelihood of developing an EAF.(25) This type of fistula is 
almost exclusively described in traumatically injured or critically ill patients.(29) This 
patient population present with a unique risk for fistulation due to intentional or 
unintentional bowel injury, intra-abdominal infections and decompression for 
abdominal compartment syndrome.(29)  
 
A very important finding from this study was the ability to send four patients home for 
a median of 32,5 days. Despite the very high output, patients were able to maintain 
nutrition and fluid status outside the hospital without IV fluid or nutrients. Owing to 
the poor socioeconomic circumstances of a large portion of patients in the South 
African public hospital sector, HPN is almost impossible to achieve safely. Therefore 
patients presenting with IF would be confined to hospital if they require PN or IV fluid 
as part of their treatment. In this patient population, where the median length of stay 
was 93 days in the unit, the ability to discharge patients for almost a third of the time 
not only impacts on hospital cost and bed availability, but also plays an important 
role in the mental health and social circumstances of the patient. It should however 
be noted that patients should have the social support structure to cope at home and 
the ability to get back to hospital fast in an emergency.  
 
Only 80 fistuloclysis-related complications were reported in this study, equating to 
3,51 complications per 50 fistuloclysis catheter days. An important limitation of the 
study is the retrospective data collection. Only complications noted in patient notes 
or nursing processes could be included and it is therefore possible that a significant 
number of complications were not picked up owing to poor documentation. Leaking 
stoma bags were the most prevalent complication of fistuloclysis in this study. It 
should be noted that leaking stoma devices is not directly caused by fistuloclysis but 
is rather a result of the technique applied in the South African setting, due to the fact 
that specific stoma pouches are not available. This necessitates the need to punch a 
hole in the stoma pouch to feed the catheter through which compromises the 
integrity and predisposes it to leakage.  
 
PN support for patients with IF is associated with several side effects, hepatobiliary 
dysfunction being one of the most prevalent and severe complications.(31) Liver 
decompensation associated with long-term PN support is referred to as intestinal 
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failure associated liver disease (IFALD).(31) This includes biochemical (increased liver 
enzymes) and histological (steatosis, cholestasis and cirrhosis) alterations.(17) IFALD 
is defined as persistently elevated serum transaminases, 1,5 times the upper limit of 
normal in the presence of SBS.(31) It is often difficult to determine whether the liver 
dysfunction is a consequence of SBS, nutrition therapy or drug therapy.(31) Three 
types of hepatobiliary disorders are associated with IFALD namely steatosis, 
cholestasis and gallbladder stones or sludge.(31,32) Steatosis occurs predominantly in 
adults, is usually benign and patients remain asymptomatic.(32) It presents with mild 
to moderate elevation of aminotransferase (ALT and AST) levels and with a lesser 
degree of elevation in ALP and bilirubin. Typical onset occurs after two weeks of PN 
therapy and may even return to normal with continuation of PN therapy. Progression 
to fibrosis and cirrhosis might be a consideration in patients receiving long-term PN 
support. Cholestasis predominantly occurs in children but might also be a 
complication in adult patients receiving long-term PN support. It is characterised by 
elevations in ALP, GGT and conjugated bilirubin with or without clinical jaundice. 
ALT and AST might also be elevated. Elevated conjugated bilirubin is considered the 
prime indicator for cholestasis. Cholestasis is a serious complication, which may 
progress to cirrhosis and liver failure. If PN is stopped before irreversible hepatic 
damage occurs, complete recovery is expected and levels usually return to normal 
within one week to two months. Gallbladder stasis may lead to development of 
gallstones or gallbladder sludge with subsequent cholecystitis. This condition occurs 
in both paediatric and adult patients receiving PN support.(32) 
 
In the current study biochemistry done on day 0 of fistuloclysis revealed some of the 
characteristics of IFALD with elevated LFTs. Median bilirubin remained within normal 
limits, but some patients did present with high levels and the aim was to improve on 
that. This aim was achieved, as is evident in the improvement of the range with the 
maximum value for total bilirubin within the normal range and the maximum for 
conjugated bilirubin just above the cut-off level of 6 μmol. It did not reach statistical 
significance, but the median LFTs showed a downward or static trend following the 
initiation of fistuloclysis and withdrawal of PN. (Figure 3, Figure 4, Figure 5)  
 
Apart from PN and duration of PN support, length of bowel remnant plays a role with 
an increased risk of cholelithiasis with a remnant bowel of less than 120cm and if the 
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terminal ileum is resected. (31) A bowel remnant of less than 50cm is associated with 
a significant increased risk of IFALD.(32,33) SBS is associated with disruption of 
enterohepatic circulation and alterations in bile acid metabolism and excretion 
predisposing patients to the development of IFALD. Bacterial overgrowth occurs 
when bacteria normally found in the colon and lower small bowel populates the 
upper small intestine. It is thought that these bacteria could potentially produce 
hepatotoxins, which could cause hepatic injury. Bacterial overgrowth may also 
contribute to cholestasis by promoting deconjugation of bile acids, preventing their 
reabsorption. Furthermore, patients who are unable to tolerate any enteral nutrition 
are more prone to developing IFALD than those who can tolerate even very small 
amounts. Lack of enteral stimulation reduces hepatocellular bile acid and bile 
secretion, and reduced gallbladder contractility. Biliary sludge could develop as a 
result of reduced activity. Bacterial and fungal sepsis also correlates strongly with 
cholestasis. Sepsis causes systemic inflammation of the liver due to the release of 
pro-inflammatory cytokines which result in altered membrane function of the bile 
canaliculi and subsequent reduced bile flow.(32) This should be taken into account 
since many of these factors could be present in IF patients and would influence liver 
parameters. If PN could, however, be removed from the equation and replaced with 
fistuloclysis, this could aid in improving liver parameters by means of a number of 
mechanisms.  
 
Studies show that fistuloclysis is more effective in improving liver function than 
enteral nutrition alone. This may in part be attributable to cholecystokinin (CCK), 
which is produced by the endocrine cells in the duodenum and upper jejunum, 
stimulating gallbladder contractility and bile secretion. CCK is excreted in response 
to fat, protein and amino-acids in the duodenum. Trypsin-sensitive monitor peptide in 
the upper intestinal lumen is another potent CCK-releasing factor, but might be lost 
through the fistula output. Therefore restoring continuity of the digestive system 
through fistuloclysis might improve CCK secretion and improve cholestasis. 
Fistuloclysis provides enzymes, including salivary amylase, gastric pepsin and 
pancreatic enzymes, as well as, bile acids necessary for optimal enteral nutrition 
utilisation. The fistula effluent also has the perfect pH to activate proenzymes and 
appropriate enzyme components for optimal enteral nutrition absorption. In the intact 
gut, bile acids secreted in the duodenum are absorbed in the terminal ileum and 
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recycled to the liver. In the patient with a fistula or when the distal part of the small 
bowel is in discontinuity this cycle is interrupted, leading to a lack of bile acids and 
subsequent malabsorption of fatty acids, phospholipids and fat-soluble vitamins. With 
fistuloclysis, the enterohepatic circulation of bile acids can be restored with 
improvement in nutritional status.(7) 
 
In the current study there was a statistically significant increase in serum albumin 
between day 0 and day 28 (p=0.001). This should, however, be interpreted in 
conjunction with sepsis indicators to ensure true reflection of nutritional status. The 
only available indicator in the current study was white cell count, which improved 
from 12,24x109/L on day 0 to within the normal range, namely 9,88x109/L, at day 28. 
The increase in serum albumin was associated with a decrease in white cell count 
therefore it cannot be concluded that the improvement was associated with an 
improvement in nutritional status alone. Teubner et al. and Wu et al. both reported 
improvement in nutritional status associated with fistuloclysis, and this included 
significant increases in serum albumin levels.(6,7) 
 
There was a median decrease in body weight of 3 kg during the period of 
fistuloclysis at a median rate of 300g body weight loss per week. When the individual 
weight changes were considered, as displayed in Figure 6, this was influenced by a 
weight loss of 15kg in one individual who had been in the unit for an extended 
period. A number of patients showed static weight trends and some showed 
improvements in weight. Patients are often admitted to the IF unit following 
aggressive fluid resuscitation, it is therefor not unexpected that there will be an initial 
decrease in weight as excessive fluids are mobilized. This should however stabilize 
followed by an improvement in weight. This improvement was not observed in this 
patient cohort. Hydration status could account for small fluctuations observed in body 
weight. Furthermore these patients are confined to the hospital environment where 
mobilization is often limited resulting in inadequate replenishment of lean body mass. 
Despite the median decrease in weight, patients still underwent successful definitive 
surgical intervention with minimal complications. It could therefore be argued that the 
loss of weight observed did not have clinical significance in this patient cohort.  
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There were only two deaths in this group of patients who were managed by means 
of fistuloclysis. None of the patients whose medical notes were unobtainable passed 
away, bringing the total available mortality data to 20 patients (n=2/20, 10%). This 
was in keeping with the mortality rate of 13,5% among the 37 patients who were not 
managed with fistuloclysis. This correlated well with literature reporting in-hospital 
mortality resulting from type 2 IF as between 9,6%-13%.(8) In the current study, both 
patients who died succumbed prior to undergoing definitive surgery. One patient died 
as a result of respiratory arrest secondary to a suspected pulmonary embolism while 
the other death was due to pneumonia. Three patients developed complications after 
definitive surgery. This included two patients who developed anastomotic leak and 
enterocutaneous fistulae, which resolved spontaneously. One patient required a 
relook laparotomy on the basis of on going abdominal symptoms, which proved 
negative. The patient subsequently had an uneventful postoperative course. 
 
The data presented here was extrapolated from the same database as a study 
previously published by Coetzee et al.(34) Due to different study periods, inclusion 
criteria and missing patient folders there were however significant differences 
between the final patient cohorts. The research questions and statistical analysis and 
interpretation of the data were also significantly different between the studies.  
Conclusion 
From this study and other available literature, it is evident that fistuloclysis can 
successfully replace PN support in selected patients suitable for this approach. 
Despite the fact that improvement in LFTs and bilirubin, which remained within 
normal limits, did not reach statistical significance and patients lost a median of 3kg 
during the period of fistuloclysis, the patients were weaned off PN and underwent 
surgery with acceptable complications and all attained digestive autonomy. The main 
aim in the management of IF is to perform definitive surgery successfully with 
minimum postoperative complications and that was achieved well in this study.  
 
Although it cannot be concluded that fistuloclysis is superior to conventional methods 
of management of IF, it can be stated that it is at least equal. Furthermore, 
fistuloclysis was associated with minor complications, while PN is far more 
precarious in terms of risk for line sepsis and development of IFALD. Fistuloclysis is 
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less costly and has the potential to be done safely in the home environment, which 
would allow for patient discharge prior to definitive surgery in selected cases.  
 
Fistuloclysis is a novel method of nutritional support for a complicated patient 
population. It is associated with fewer complications and reduced costs when 
compared with conventional methods, and it produces comparable outcomes in 
terms of mortality and postoperative complications. Fistuloclysis should be 
considered as a treatment modality for patients with IF in other care facilities with the 
available expertise and commitment within the multidisciplinary team.  
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4.2 Objective 2 
To present one purposefully selected patient case study 
Nutritional management of a complicated surgical patient by means of 
fistuloclysis. 
South African Journal of Clinical Nutrition 2014; 27 (4): 230 – 23
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4.3 Objective 3 
To investigate the current management of type 2 and type 3 intestinal failure 
patients in the tertiary hospitals in South Africa, as well as the perceptions and 
opinions regarding fistuloclysis as a management option for this patient population 
amongst doctors, stoma sisters and dietitians involved in their care. 
 
Due to the very poor response rate to the questionnaires distributed to doctors and 
stoma therapists the results for these two groups will only be discussed briefly in 
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4.3.1 Responses from dietitians 
The current management of intestinal failure patients in South 
African hospitals by dietitians, and their opinions and perceptions 
regarding fistuloclysis as a treatment option 
Du Toit A a,b, Boutall ABTc, Blaauw Ra 
a
: Division of Human Nutrition, Faculty of Medicine and Health Sciences, Stellenbosch University 
b
:Department of Dietetics, Groote Schuur Hospital, Cape Town 
c
: Department of Surgery, Groote Schuur Hospital, Cape Town 
Introduction 
Intestinal failure (IF) and the complications and cost associated with parenteral 
nutrition (PN) support in this patient population are a reality in the South African 
context. Owing to the nature and complexity of IF, it often requires long-term 
hospitalisation and PN support to improve or maintain nutritional status, allow for 
enough time between surgeries, and time to treat current complications before a 
patient can be considered for definitive surgery.(1,2) In a recent cost analysis done by 
the National Department of Health, PN was found to be one of the top 10 pharmacy 
expenditures, contributing major costs to patient treatment.(3)  
 
Fleming and Remington first defined the concept of IF in 1981 as “a reduction in the 
functional gut mass below the minimal amount necessary for adequate digestion and 
absorption of food”.(4–6) The definition of IF proposed by Fleming and Remington has 
since been revised by other authors to include, among others, duration, stage, 
degree of impairment, underlying causes etc. In 2015 the European Society for 
Clinical Nutrition and Metabolism (ESPEN) published recommendations on the 
definition and classification of IF in adults. These recommendations included a 
definition of IF, a functional and pathophysiological classification for acute and 
chronic IF, and a clinical classification of chronic IF. According to the ESPEN 
classification, IF can be defined as the reduction of gut function below the minimum 
necessary for absorption of macronutrients and/or water and electrolytes, such that 
intravenous (IV) supplementation is required to maintain health and/or growth.(4) The 
need for IV replacement of nutrients and/or fluids is used as the surrogate marker for 
the diagnosis of IF in the absence of readily available complex metabolic studies.(4,7) 
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Micronutrients are not included in the definition, and micronutrient deficiencies alone 
due to gut impairment are not classified as IF. In situations where the absorptive 
ability of the gut is impaired, but not to the degree that IV supplementation of fluid 
and/or nutrients is required to maintain health and growth, the condition can be 
referred to as “intestinal insufficiency”.(4)  
 
Fistuloclysis, i.e. feeding of intestinal effluent via a distal intestinal fistula or stoma, is 
an effective and feasible way of managing patients with IF and is often the only 
alternative to PN support.(8,9) Enteral nutrition (EN), apart from being less costly, has 
considerable advantages over PN support.(10) The advantages include improved gut 
barrier function, reduction in infectious morbidity and improved immune function.(10)  
In a resource-scarce environment we need to explore novel treatment options that 
are effective in promoting the medical and nutritional status of patients, while 
minimising risk, improving quality of life and reducing cost. The researchers believe 
that fistuloclysis is a feasible, but underutilised, option for the management of IF in 
the South African context. The motivation for this study was to gather information 
regarding the management of IF in other institutions as well as the opinion and 
perceptions of dietitians regarding fistuloclysis. This information will be useful in 
terms of establishing equipment and training needs and the readiness of institutions 
to adapt to a novel nutritional management solution.  
Methods 
Study population 
Dietitians working in South Africa who are involved in the nutritional management of 
type 2 and type 3 IF patients were included in the study population. Dietitians not 
currently actively involved in the nutritional management of IF patients were 
excluded. Dietitians currently working at Groote Schuur Hospital were also excluded 
since the investigators were acquainted with the management of IF patients at this 
institution and the aim of the survey were to determine the management of this 
patient population in other institutions. Indeed, the principle investigator is 
responsible for the nutritional management of IF patients at this institution. 
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Study design and methods 
A descriptive observational study of the current management of type 2 and type 3 IF 
patients in South African hospitals, as well as of the perceptions and opinions of 
dietitians about fistuloclysis as a treatment option for IF was done by means of a 
self-administered questionnaire.  
The questionnaire was developed in consultation with professionals currently 
involved in the management of IF patients in Groote Schuur Hospital where 
fistuloclysis has been implemented successfully. The questionnaire was managed 
through the web-based system, Survey Monkey, and contained an introduction page 
giving the potential respondents a background to the study and the investigators. In 
an attempt to adhere to the inclusion and exclusion criteria questions were built into 
the questionnaire that would exit the respondents from the survey early if they did 
not fit the criteria. If respondents did fit the inclusion criteria but were not familiar with 
the term fistuloclysis they were given a brief explanation and allowed to continue with 
the survey. All questions required an answer before the participant could proceed to 
the next question. If a participant responded negatively to questions that had other 
questions following them the questionnaire automatically skipped to the next 
unrelated question. The survey was planned to take approximately 15 minutes to 
complete. 
 
An e-mail containing a link to the Survey Monkey questionnaire was sent out via the 
Association for Dietetics in South Africa (ADSA) and the South African Society for 
Parenteral and Enteral Nutrition (SASPEN) mailing lists to recruit dietitians for 
participation. A second e-mail was sent out two weeks after the first as a reminder. 
The survey remained open for completion for a total of four weeks.  
Statistical analysis 
The data obtained from Survey Monkey were downloaded in the form of an Excel 
spread sheet. The data were analysed by the principle investigator and reported as 
descriptive statistics.  
Ethics 
Ethics approval was obtained from the Stellenbosch University Health Research 
Ethics Committee (Reference # S14/09/177). 
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Questionnaires were completed anonymously through Survey Monkey and 
willingness to participate in the study was regarded as informed consent. 
Results 
Twenty-seven dietitians participated in the survey. The spread of private to public 
sector as well the level of care they were involved in is displayed in Figure 1. There 
was almost a 50:50 split between participation from the public and private sectors 
with the majority of respondents from the public sector being situated in secondary or 
tertiary healthcare institutions. 
 
Figure 1: Area of occupation and level of care of respondents 
 
Six respondents were excluded from the survey since they were not directly involved 
in the nutritional management of IF patients in their current practices. The 21 
respondents currently involved in the management of IF patients continued with the 
survey. The respondents’ years of experience in the field of IF are displayed in 
Figure 2. The majority of respondents, i.e. 67%, had been involved with patient 
management in this field for one to five years.  
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Figure 2: Respondents’ years of experience in the management of intestinal failure patients 
 
Respondents were given eight options of clinical conditions or presentations and 
were asked to indicate which of these they would regard as IF (more than one option 
could be indicated). The results are displayed in Figure 3. Only 18 out of 21 
respondents answered this question and continued with the survey. All of the 
respondents indicated that high fistula outputs (n=18/18, 100%) would be defined as 
IF, while ileus (n=11/18, 61%), short bowel syndrome (n=12/18, 67%) and bowel 
obstruction (n=14/18, 78%) were also often indicated as IF.  
 
 
Figure 3: Conditions regarded as intestinal failure by respondents 
Seventeen of the 18 respondents answered the question regarding whether they 
were familiar with the term fistuloclysis. If they answered “yes” to this question, they 
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were asked to provide a short explanation of what they understood by this term. 
Eleven of the 17 respondents indicated that they were familiar with the term, but 
three of them did not give any explanation and were therefore regarded as not being 
familiar with the term. This resulted in the majority (n=9/17, 53%) of respondents not 
knowing what fistuloclysis was. The data were analysed for the 47% (n=8/17) who 
responded that they were familiar with the term fistuloclysis to determine which area 
of care they practice in (Figure 4). The majority of the respondents familiar with the 
term fistuloclysis were situated in the public sector in tertiary hospitals. All eight 
participants who indicated that they were familiar with the term gave a correct 
explanation regarding what they understood by the term fistuloclysis.  
 
 
Figure 4: Distribution of dietitians familiar with the term fistuloclysis 
 
Fourteen respondents responded to the question whether they had ever used 
fistuloclysis before in their current or previous settings. Of them, 43% (n=6/14) had 
used it before. Notably, 50% of respondents who were familiar with the term had 
never used fistuloclysis before as a treatment method. Of the 14 respondents only 
four (n=4/14, 28%) were using fistuloclysis in their current settings. Of these two 
(n=2/4, 50%) were in the public sector in secondary hospitals, while one was in a 
tertiary institution (n=1/4, 25%) and one in the private sector (n=1/4, 25%). Two 
indicated that they had only used it on one or two patients in the preceding two years 
and did not have much experience with it. Three of the four (n=3/4, 75%) using 
fistuloclysis thought it was a practical and achievable option for nutrition support. 
One respondent said “If it is something that is effective then it would be great if it 
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became more common practice. I must admit I have not researched it but will 
definitely after this survey.” The three respondents indicated that patients 
experienced fistuloclysis as an acceptable mode of nutrition support. One comment 
was: “Our patient actually preferred it to the TPN. She found the TPN catheter site 
very uncomfortable”  
 
PN was indicated as the treatment modality most commonly used in institutions 
where fistuloclysis was not done or when fistuloclysis was not possible for an 
individual patient. All of the respondents (n=12/12) indicated that they used PN either 
as a first line treatment early in the management course, or would revert to PN if 
other methods like EN or oral intake failed. Failing of enteral or oral nutrition seemed 
to be regarded as an increase in output from the stoma or fistula above a tolerable 
level.  
 
Respondents were given five common stumbling blocks for the successful 
implementation of fistuloclysis and were asked to indicate which were applicable in 
their opinion/institution. Reasons associated with failure to implement fistuloclysis 
are presented in Figure 5. All the respondents agreed that lack of training (n=12/12, 
100%) contributed to the unsuccessful implementation of fistuloclysis in their 
institutions. The second most prevalent reason was resistance from clinicians and 
nursing staff (n=9/12, 75%), with lack of equipment (n=7/12, 58%) ranked third.  
 
Figure 5: Reasons identified for unsuccessful implementation of fistuloclysis 
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All respondents agreed that they would consider fistuloclysis as a method of nutrition 
support if they had more information and a protocol available to guide the process. 
Discussion 
There are currently 4 250 dietitians registered with the Health Professions Council of 
South Africa (HPCSA). The South African Society for Parenteral and Enteral 
Nutrition (SASPEN), which represent dietitians working in the field of clinical 
dietetics, has around 200 registered members. Furthermore, although South African 
statistics are not available, IF appears to only involve a small percentage of the 
population. Data from hospitals in England estimated that the incidence of IF might 
be as high as 18 per million of the population per year, this was based on patients 
receiving PN support for at least 14 days.(11) If this were extrapolated to the South 
African context the number would amount to roughly 970 patients per year. It could 
therefore be postulated that the number of dietitians working in the field of clinical 
dietetics and with IF patients is quite limited. This may be the reason for the small 
number of responses received. The initial study methodology was aimed at 
investigating only the practices at other tertiary institutions, which would have 
produced a maximum of 11 responses; therefore the response rate of 27 is regarded 
as successful and fairly representative of current clinical practice. There was good 
representation within the 27 participants of the public as well as private healthcare 
sectors. Most participants from the public setting were involved in care at secondary 
and tertiary level where management of IF patients are expected.  
 
What dietitians regard as IF is a diverse number of clinical presentations and 
conditions resulting in increased losses and decreased absorption of nutrients. This 
is in line with the definition of IF provided ESPEN. ESPEN classifies IF according to 
a functional and pathophysiological classification.(4) The functional classification sub-
divides IF into three types, based on the onset and expected metabolic impact and 
outcome.(4,12,13) Type I IF is often acute, short-term and usually self-limiting, resolving 
within 14 days on conservative management.(11,14–16) Type II IF refers to a prolonged 
acute condition usually occurring in metabolically unstable patients and requires the 
care of a multidisciplinary team, with intravenous supplementation for weeks or 
months.(11) Type III IF refers to a chronic condition in a metabolically stable patient, 
which could be irreversible and might require intravenous support for months or 
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years.(4,11,14) The pathophysiological classification includes five primary pathologies: 
short bowel syndrome (SBS), intestinal fistula, intestinal dysmotility, mechanical 
obstruction and extensive small bowel mucosal disease.(4)  
 
When asked to indicate conditions that can be regarded as IF, 67% of the 
respondents indicated that they associate SBS with IF. SBS could result from 
extensive surgical resection due to a number of indications or as a result of 
congenital disease of the small intestine.(4,17–19) Clinical manifestation of SBS is 
associated with less than 200cm of small bowel remaining in continuity.(4,17,20) 
Although the length of the remaining bowel correlates with a patient’s degree of 
nutritional autonomy, the remaining anatomy, the integrity and function of the 
available bowel, the underlying condition and the ability of the bowel remnant to 
adapt are big determining factors.(4,13,18,19,21) The pathophysiological manner in which 
SBS causes IF is due to extensive loss of absorptive surface area.(4,20) SBS is the 
leading cause of type 3 IF and accounts for around 75% of adults receiving home 
parenteral nutrition (HPN) in Europe.(4) 
 
Intestinal fistula is defined as an abnormal communication between two epithelium-
lined surfaces.(2,4,8,22–24) Classification of fistulae can be done on the basis of the 
anatomy, physiology or aetiology.(8,23–26) Anatomically, a fistula is classified 
according to the segment of gut it originates from and the organs involved.(4,24,27) The 
physiological classification for fistulae is based on output and defines less than 
200ml per day as low output, while 200–500ml per day is classified as moderate 
output. (4,24–26,28) Effluent of >500ml per day in the fasted state is considered a high-
output fistula. (4,22,24,25,28) Fistulae can be classified as primary (type 1) or secondary 
(type 2) according to the aetiology.(23,29) Primary fistulae develop as a result of 
underlying disease, while secondary fistulae are the result of insult or injury to 
previously healthy bowel.(23,29) The most common cause of intestinal fistulae are 
surgical complications, amounting to 75–85% of cases.(4,8,22,25,26,30–32) The remaining 
15–25% of fistulae arise from the underlying pathology, with Crohn’s disease being a 
major contributor.(4,31,32) The pathophysiological manner in which fistulae cause IF is 
by the loss of enteric content through a proximal opening or by bypassing a 
significant segment of gut in the case of internal enteroenteric fistulae. (4,27,23) All 
respondents agreed and indicated that a high-output fistula is associated with IF.  
Stellenbosch University  https://scholar.sun.ac.za
 95
The term intestinal dysmotility refers to the presence of a disorder that impairs the 
propulsion of gut content in the absence of an obstruction.(4) It can be further divided 
into loco-regional, indicating an isolated segment is affected (eg. Achalasia, 
gastroparesis) or multi-regional, involving more than one part of the gastrointestinal 
tract, often the small intestine.(4) Intestinal dysmotility can present as type 1 IF in the 
case of acute postoperative ileus or critical illness associated ileus. (4) Dysmotility 
often presents as a result of systemic or intra-abdominal inflammation as type 2 IF.(4) 
Chronic IF associated with dysmotility is referred to as chronic intestinal pseudo-
obstruction (CIPO) with the ‘pseudo’ indicating the absence of an occluding lesion. (4) 
The primary pathophysiology in intestinal dysmotility that gives rise to IF is the 
intolerance to oral or enteral nutrition, resulting in inadequate nutrient intake.(4) 
Generally the mucosal surface is preserved.(4) Secondary mechanisms that play a 
part are the malabsorption of nutrients due to bacterial overgrowth in stagnant bowel 
loops, as well as increased intestinal losses of fluids and electrolytes due to 
increased secretions in dilated bowel loops.(4) Causes of IF correctly indicated by 
respondents that could be classified as intestinal dysmotility included ileus (61%), 
vomiting (28%) and high nasogastric output (33%) 
 
Mechanical obstruction refers to a physical abnormality affecting the intestine.(4) This 
could be intraluminal (eg. foreign bodies), intrinsic (eg. stenosis), or extrinsic (eg. 
frozen abdomen).(4) Furthermore these might be of benign or malignant origin.(4) It 
could present as a type 1 IF which presents acutely and resolves within days with 
conservative management or surgery. It might also present as a type 2 or 3 IF with a 
prolonged course.(4) The pathophysiological mechanism of IF due to mechanical 
obstruction is the spontaneous or prescribed ceasing of oral intake.(4) Secondary to 
that, increased intestinal losses of fluids and electrolytes into distended bowel loops 
as well as losses due to vomiting or increased nasogastric drainage adds to the 
manifestation of IF.(4) Vomiting and high nasogastric output, indicated by 
respondents, as causes for IF, could also be the clinical manifestation of bowel 
obstruction. Furthermore, bowel obstruction per se was indicated as a cause of IF by 
78% of respondents. 
 
Extensive small bowel mucosal disease refers to a condition where there is intact or 
almost intact but inefficient mucosal surface.(4) There is a reduction in nutrient 
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absorption and/or an increase in nutrient loss via the mucosa to the point where the 
nutritional needs cannot be met, e.g. coeliac disease, radiation enteritis and protein-
losing enteropathy.(4) Chronic diarrhoea was correctly indicated as IF by 56% of 
respondents.  
 
Only 47% of respondents were familiar with the term fistuloclysis and could give a 
correct explanation, with the majority of them currently working in tertiary hospitals. 
No literature could be obtained regarding international surveys evaluating the 
knowledge and practices of dietitians, specifically with regard to the nutritional 
management of complicated surgical patients. One available study evaluated the 
knowledge and attitudes of surgical trainees towards nutrition support and compared 
it to the knowledge and attitudes of dietitians working in the same field.(33) This study 
asked a series of multiple-choice questions related to nutrition in the surgical patient 
as well as the attitudes of respondents regarding nutrition.(33) The finding from this 
survey was that dietitians generally scored higher than surgical trainees in the 
knowledge questions, i.e. 88% versus 47%.(33) The knowledge of trainees improved 
with years of experience with the highest scores achieved by trainees with >3years 
of experience at 58%.(33) With regard to attitudes towards nutrition support, 100% of 
dietitians felt that they had adequate knowledge, while only 47% of surgical trainees 
were confident about this.(33) Despite the fact that fistuloclysis is successfully 
implemented internationally, there is no literature available which specifically 
evaluates the knowledge and practices of the multidisciplinary team with regard to 
fistuloclysis to which our findings could be compared. This study therefore adds 
useful information to identify gaps and barriers in the implementation of fistuloclysis 
in the South African context.  
 
On further investigation, it was determined that 50% of respondents who were 
familiar with the term fistuloclysis had never used it before. This is a positive finding 
since it indicates awareness concerning fistuloclysis. Since training and resistance 
from nursing staff and clinicians were indicated as the two leading reasons for 
unsuccessful implementation of fistuloclysis, awareness could potentially be turned 
into practice through appropriate training and advocacy.  
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Although six out of 14 respondents had used fistuloclysis in practice before, only four 
were at that time using the method, but indicated it was not a regular procedure in 
their institutions. Surprisingly, two of the four respondents using fistuloclysis at that 
time were situated in secondary hospitals within the public sector. This was an 
unexpected finding, since the assumption would be that patients with IF would be 
managed at a higher level. It is encouraging that fistuloclysis can be successfully 
implemented at this level. The respondents did indicate that this was not the norm for 
nutritional management at their institution and that it had only been done in respect 
of one or two patients over a two-year period. All the dietitians who had used it 
before found it to be successful and well received by patients.  
 
Nutrition support via the PN route was indicated as the route of choice most often 
used by respondents, either as a first line treatment or after enteral or oral nutrition 
had failed. Respondents indicated that they regarded enteral or oral nutrition to be 
unsuccessful if they experienced an increase in the fistula or stoma output. In the 
case of IF, the preferred mode of nutrition delivery would depend largely on the 
underlying cause, and the responses could be regarded as in accordance with 
evidence-based guidelines. All SBS patients will require PN support in the immediate 
postoperative phase to maintain nutritional status.(34) SBS with permanent PN 
dependence is strongly related to a small bowel length of <50cm post duodenum and 
to the absence of ileum and/or colon in continuity.(35) Values separating transient and 
permanent IF differ according to anatomy and are 100cm for an end-enterostomy, 
65cm for a jejunocolic anastomosis and 30cm for a jejunoileocolic anastomosis.(35) 
Bowel adaptation usually occurs within the first two years following the last surgical 
intervention.(19,20,34) The degree of adaptation is related to the extent of the resection 
as well as the anatomy of the remnant bowel.(19,36,37) Structural and functional 
changes occur in the remnant bowel that improves nutrient and fluid 
absorption.(19,20,36,37) There is no evidence of any functional or structural adaptation in 
patients with end-jejunostomies, therefore change in nutritional and fluid needs are 
unlikely with time. (38) According to consensus data most of the adaptation occurs 
within the first two years following resection, although some studies have suggested 
significant improvement beyond two-years.(36) Adaptation after two years is 
uncommon and limited to a maximum improvement of 5–10% in absorptive 
capacity.(34) In the case of fistulae enteral nutrition support is the preferred route of 
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nutrition support, unless it increases fistula output dramatically or causes increased 
abdominal pain or exacerbates diarrhoea.(5,22,30) Bowel absorptive capacity should be 
sufficient for successful implementation of enteral nutrition support, and patients with 
fistulae should be able to tolerate polymeric enteral formula, unless the patient has 
less than 120cm of bowel left, have documented intolerance to polymeric enteral 
feed or experiences high fistula output.(23,28) In that case, the patient should be 
changed to a semi-elemental or elemental enteral product. (28) The literature suggests 
that absolute contraindications to enteral nutrition include bowel discontinuity or 
insufficient bowel length, usually <75cm.(8,28) This however might not be an absolute 
in practice. In the case of intestinal dysmotility and bowel obstruction, the primary 
pathophysiology resulting in IF is the inability to successfully utilise the enteral or oral 
route, therefore PN would be indicated as the primary route of nutrition support.(4) 
The same would apply in the case of extensive small bowel mucosal disease, where 
intestinal nutrient absorption is completely impaired and the enteral or oral route 
becomes futile.(4)   
 
All respondents indicated that they would consider using fistuloclysis as a means of 
nutrition support if they could gain the knowledge through training and had protocols 
available to guide the process. 
Conclusion and recommendations 
It is evident from the responses that dietitians are positive about the concept of 
fistuloclysis and are willing to apply it in patient care. It would have been valuable to 
have had sufficient information available regarding the opinions and perceptions of 
nursing staff and doctors on fistuloclysis, as this would have provided a more 
comprehensive picture regarding the management of these complex surgical cases. 
Based on the available data, we can however confirm that the employment of 
fistuloclysis in the management of adult IF patients in South African hospitals is 
underutilised. There is awareness among dietitians participating in this study 
regarding fistuloclysis as a treatment modality. Lack of training has been identified as 
one of the biggest stumbling blocks in the successful implementation of fistuloclysis. 
This could be addressed through training and protocol development. The training 
and protocols should include doctors and nursing personnel since nursing and 
clinician resistance have been identified as stumbling blocks in the implementation of 
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fistuloclysis, whereas they could play a pivotal role in the successful execution 
thereof.  
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4.3.2 Responses from stoma therapists 
The current management of intestinal failure patients by stoma 
therapists in South African hospitals, and their opinions and 
perceptions regarding fistuloclysis as a treatment option. 
Results 
There were ten responses to the survey from stoma therapists. Out of the 10, seven 
were excluded due to the fact that they indicated that they were currently working at 
Groote Schuur Hospital. Out of the three eligible for inclusion one was not currently 
responsible for the management of intestinal failure (IF) patients and were 
subsequently excluded. This left two stoma therapists who were working in the 
private sector. Both had >10years experiece in the management of intestinal failure 
patients. Only one of the two procedeed with further questions, the other one did not 
finish the questionnaire.  
 
This therapist was familiar with the term fistuloclysis and gave the correct 
explanation of the term. "A means of re feeding. i.e. insertion of proximal limb efflux 
back into the distal limb.  It is a successful and cost effective method of nutritional 
support for patients who would otherwise require parental feeding." This therapist 
had been involved in the placement of a fistuloclysis catheter before and believed 
he/she had the skill and knowledge to successfully do it. They are currently using 
fistuloclysis as a means of nutrition support at the private institution where the 
therapist was employed and gave a correct explanation of the process that is 
followed: "The distal limb is intubated with a Foley catheter. A stoma appliance 
/fistula bag is attached to the fistula to collect the efflux from the proximal limb. The 
output is collected and then strained using a stainless steel sieve. The sieved 
contents are put into an enteral feeding bag and connected to a giving set. The set is 
attached to the Foley catheter and the feed is introduced slowly into the distal limb. A 
drop monitor is required. Prior to re-feeding - patency of the distal limb must be 
confirmed." Complications associated with fistuloclysis identified by the respondent 
were tube dislodgement, blocked tubes, bags leaking and blocked giving sets. 
Stumbling blocks in the successful implementation of fistuloclysis identified by the 
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respondent were lack of training of staff and staff shortage. The respondent indicated 
that he/she would be interested in using fistuloclysis as a means of nutrition support 
if there were a detailed protocol available. 
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4.3.3 Responses from doctors 
The current management of intestinal failure patients by doctors in 
South African hospitals, and their opinions and perceptions 
regarding fistuloclysis as a treatment option. 
Results 
There were four responses on the survey for doctors managing intestinal failure. 
Bearing in mind that only eight centres were contacted, this is a 50% response rate 
and was regarded as good. With regard to the area the doctors worked in, there was 
a 50:50 split between participants practising in both the private and public sector 
(n=2/4, 50%) and in the public sector only (n=2/4, 50%). All four respondents fitted 
all of the inclusion criteria and continued with the survey. With regard to years of 
experience, one respondent had one to five years’ experience (n=1/4), while 50% 
had between six and ten years’ experience (n=2/4). The other respondent indicated 
>10years’ experience.  
 
When asked what they would define as intestinal failure (IF), 25% indicated high 
nasogastric drainage (n=1/4), 50% indicated high stoma losses (n=2/4), 75% 
indicated short bowel syndrome (n=3/4) and all respondents indicated high fistula 
outputs. Chronic diarrhoea, bowel obstruction and ileus were not associated with 
intestinal failure by any of the respondents. None of the respondents had a 
dedicated IF unit at their facility.  
 
The aetiology of IF indicated was postoperative complications by 75% of the 
respondents (n=3/4) and trauma indicated by one respondent (n=1/4, 25%).  
Two out of four respondents indicated a waiting period of six to twelve weeks at their 
institution before a patient would be considered for definitive surgery. The other two 
indicated slightly longer periods of 13-18 weeks and >24 weeks respectively.  
With regard to keeping patients nil by mouth, 75% of respondents indicated that this 
was common practice in their facilities (n=3/4). The reason for keeping patients nil by 
mouth was associated with fistula output in all cases. Three out of the four indicated 
that a fistula output of >1 000ml over 24hours would be regarded as too high while 
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the other respondent indicated that patients with a fistula output of 500-999ml would 
be kept nil by mouth. 
 
Two out of the four respondents (50%) indicated that it was routine practice to 
prescribe pharmacological agents to decrease output or transit time. Both indicated 
the use of Loperamide, with the dosage ranging between two tablets per day and up 
to a maximum of 16 tablets per day. One of the two respondents indicated that 
Codeine Phosphate is commonly used at a dosage of 30mg per os 12 hourly up to a 
max of 120mg per os 12 hourly. One of the two respondents indicated that octreotide 
has been used, but not often enough for him or her to remember the dosage while 
the other one indicated using it at a dosage of 100 micrograms 6 hourly. 
 
All four respondents indicated that they were familiar with the term fistuloclysis and 
gave an explanation inline with the correct definition of the term. When asked 
whether they thought it was a practical and achievable option for nutrition support in 
a South African context, 50% said yes (n=2/4) and 50% disagreed (n=2/4). One 
responded motivated his positive response with the following statement: "It is very 
poorly understood by nursing and practically difficult to do but TPN for more than a 
month is a disaster with a very high mortality in our institution. Refeeding is almost 
certainly a better option when this can be avoided". One of the respondents, who 
said no, had the following to say: "In my setting there is no specialised wards or 
dedicated nurses. I know this has been achieved at GSH and I am in awe! These are 
labour intensive patients and without a dedicated ward or unit the patients in my 
setting (State) would not get the fistuloclysis performed.  We battle just with input 
and output charting!"  
 
Two of the four respondents said that they were currently using fistuloclysis in their 
hospitals; the one respondent stated that he or she has only managed to achieve 
this in private practice and not in the public sector. The second respondent worked in 
the public sector. They stated the following with regard to the process followed: 
• "The tube is placed via a gastrostomy distal to the fistula and feeding is 
started in incremental fashion until predicted nutritional requirement is met 
and TPN is then withdrawn. The idea is to see if this type of feeding can 
replace TPN" 
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• "I have only managed to achieve this in the private sector. It is done in a High 
care or ICU setting. We try and decrease output, with medications mentioned 
before, they are all on TPN. CT to confirm no collections amenable to 
percutaneous drainage. The patient’s anatomy is visualised by radiology or 
endoscopy. We ensure there is no distal obstruction to the efferent limb. A 
catheter is placed into the efferent limb and confirmed under fluoroscopy. 
Feeding is commenced with a kangaroo pouch, and sieving of the effluent by 
the nurses. We start refeeding at 10ml per hour and increase slowly as 
tolerated.” 
 
All four of the respondents agreed that they would use fistuloclysis if there were 
more information and support available. 
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The European Society for Clinical Nutrition and Metabolism (ESPEN) definition of 
intestinal failure (IF) states that it can be defined as the reduction of gut function 
below the minimum necessary for absorption of macronutrients and/or water and 
electrolytes, such that intravenous (IV) supplementation is required to maintain 
health and/or growth. From the literature it is evident that IF can be the result of 
several aetiologies each with a unique pathophysiological cause that manifests as a 
single pathology. The management of these patients, both nutritionally and medically 
is very challenging and costly. Conclusions drawn from the study to achieve 
objective 1,2 and 3 will now be discussed.  
5.1 Objective 1 
A total of 59 patients with IF were treated in the specialised IF unit at Groote Schuur 
Hospital in Cape Town between 1 January 2009 and 31 May 2014. Seventeen 
patients, who underwent treatment with fistuloclysis, fitted the inclusion criteria and 
had accessible medical records.  
• As expected in the South African context, trauma and postsurgical 
complications were identified as the leading causes of IF in this patient 
population, contributing to 29% of the cases each.  
• 94% (n=16/17) of the patients could be weaned off PN with fistuloclysis in the 
current group therefore it can be concluded that fistuloclysis is a feasible 
option for the nutritional management of IF patients in the South African 
setting.  
• The biochemical data from this patient cohort suggests that fistuloclysis could 
improve liver parameters. This finding is support by the available literature. 
• Fistuloclysis could potentially improve serum albumin levels, as supported by 
other available literature. Albumin levels should however be interpreted in 
conjunction with inflammatory markers. 
• There was a median decrease in body weight during the period of 
fistuloclysis. The clinical significance of this finding is however unknown since 
complication rates remained minimal. 
• Managing patients with fistuloclysis makes pre-operative discharge of 
selected patients possible while conventional treatment by means of PN 
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would not have been conducted successfully outside of a hospital facility in 
the South African context. 
• Mortality and morbidity data from this patient cohort were comparable with 
that of patients receiving conventional treatment. Therefore fistuloclysis does 
not increase mortality or morbidity risk. 
• Overall the data presented from the patient population managed with 
fistuloclysis at Groote Schuur Hospital correlate well with the available 
literature and prove that fistuloclysis can be implemented successfully in a 
public hospital with limited resources in the South African setting.  
5.2 Objective 2 
This objective represents a purposefully selected case study of a patient who 
presented with type 2 IF following an abdominal gunshot.  
• Fistuloclysis can be managed successfully for an extended period of time and 
gives the option of discharge home prior to definitive surgery in selected 
patients.  
• Infusion of only a percentage of fistula effluent can still result in adequate gain 
in nutritional and fluid status. 
• Fistuloclysis is associated with minor, but manageable, catheter related 
complications.  
5.3 Objective 3 
• From the surveys done among the different occupations groups of surgeons, 
stoma therapists and dietitians it was evident that there was awareness about 
the treatment modality.  
• There are numerous stumbling blocks hampering the wider use of this novel 
treatment.  
• There was a difference in opinion among the healthcare professionals 
participating in the surveys regarding the feasibility of fistuloclysis in the South 
African setting. The doctors’ responses were mixed, with 50% agreeing and 
50% disagreeing regarding the feasibility of fistuloclysis. All dietitians and 
stoma therapists participating in the survey agreed that is it feasible in the 
South African setting. 
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• Stumbling blocks identified were: 
o Nursing workload 
o Lack of dedicated units 
o Resistance from doctors and nurses  
o Lack of training  
o Lack of information and protocols 
• Based on the explanation from the various occupation groups of the process 
followed prior to starting fistuloclysis and on how to place the catheter it 
appeared as if the technical understanding was present but that there might 
be a lack of practical experience and confidence. 
 
It was evident from the successful management of patients at Groote Schuur 
Hospital that fistuloclysis is feasible in the South African context. From the responses 
received from healthcare workers it was clear that there is an awareness of not only 
the concept of fistuloclysis but also the numerous stumbling blocks that would 
hamper the successful implementation of fistuloclysis. All of these can be addressed 
by appropriate training that could improve the utilisation of this treatment modality. 
The published case report could serve as some guidance to centres which wish to 
implement fistuloclysis to treat in their IF patients. 
5.4 Recommendations 
The following recommendations flow from this study: 
1.  Fistuloclysis as a method of nutritional support is a more cost-effective approach 
than conventional PN and may be as effective in achieving the same clinical result 
in suitable patients. Therefore, a concerted effort needs to be made to raise the 
awareness around fistuloclysis. 
2.  More dedicated treatment units should be available for the management of IF 
patients. Groote Schuur Hospital is currently the only facility with a dedicated unit. 
Ideally, each province within South Africa should have at least one referral centre 
that can manage these complex patients. 
3.  Training needs of staff should be addressed by means of occupation-specific 
training material to improve the successful utilisation of fistuloclysis. 
4.  Training material aimed at the patient level also needs to be developed to ensure 
patient cooperation and improved adherence to the treatment. 
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5.  Research should be done to investigate the cost associated with treatment of 
intestinal failure patients as well as outcomes such as mortality, length of stay in 
hospital, postoperative complications, etc. in a dedicated IF unit as against a 
general unit. It could be hypothesised that the cost of a dedicated unit would be 
cancelled out by reduction in treatment cost and improved patient outcomes.   
6. Research should be done regarding the patient’s perspective on fistuloclysis. 
Looking specifically at how acceptable patients find it as a treatment modality. 
7. There is possibly a need for the establishment of an intestinal failure interest 
group that should ideally be driven by a centre where there is experience with the 
treatment modality.  
5.5 Limitations of the study 
This study had the following limitations: 
1.  The retrospective patient record review led to limitations in the types of data 
collected, as well as unavailability of some data. 
2.  The small sample size led to limitations in terms of meaningful statistical analysis 
and interpretation of results.  
3.  Poor response from doctors and, in particular, stoma therapists limited the 
information available to make recommendations with regard to perceptions and 
opinions in these occupation groups, as well as the training and equipment needs 
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6.1 Addendum A: Data capture sheet 
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6.2 Addendum B 
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6.4 Addendum D 
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